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ABSTRACT 
It has been more than three decades since HIV (Human Immunodeficiency virus )-1 has 
been identified as the causative agent of AIDS, but an effective vaccine is still 
underway. Various vaccine vector delivery systems have been developed to enhance 
CD8+ T cell mediated immunity against HIV-1. In our laboratory, heterologous 
mucosal/systemic poxvirus prime-boost immunizations have shown to induce high 
avidity HIV-specific CD8+ T cell with excellent protective immunity. These studies 
also revealed that mucosal immunization induced lower numbers of IL-4/IL-13 
expressing HIV-specific CD8+ T cells compared to pure systemic delivery. Data 
indicated that the route of immunization can determine the quality or avidity of CD8+ T 
cell immunity and this is mainly governed by Th2 cytokines IL-4 and IL-13. 
Th 1 7 cells are a newly discovered subset of T cells that specifically produce cytokines 
IL-17A-F. It is known that these Thl 7 cells are not only involved in the pathogenesis of 
autoimmune diseases but also in the protective immunity by recruiting and activating 
neutrophils. During HIV -1 infection, these Th 1 7 producing CD4 + T cells are depleted 
and therefore considered to play a role in immunopathogenesis of HIV -1. Various 
studies have shown that both Thl and Th2 cytokines negatively regulate IL-17 A 
producing CD4+ T cells in order . to mediate their effector immune response. As 
Ranasinghe et al. have shown that IL-4/IL-13 modulate the quality of CD8+ T cells, this 
study aims to establish whether the expression of IL-17 A by HIV-specific CD8+ T cells 
is dependent on Th2 cytokines IL-4, IL-13 or Thl cytokine IFN-y. Wild type BALB/c, 
IL-4, IL-13 and STAT6 KO mice were prime-boost immunized with control vaccine 
(FPV-HIV /VV-HIV) and the expression of IL-1 7 A in spleen and lung were evaluated 
14 days post booster vaccination. Data indicated that the expression of IL-1 7 A was 
significantly enhanced in HIV specific CD8+ T cells obtained from KO mice compared 
to WT BALB/c control mice. But IFN-y did not have any effect on the IL-17 A 
' 
expression. This data clearly established that the expression of IL-1 7 A in HIV -specific 
CD8+ T .cells was modulated mainly by IL-4 compared to IL-13 (IL-4 > IL-13 ). 
To further investigate these findings and better understand the transcriptional regulation 
of IL-17A.; Wild type BALB/c, IL-4, IL-13 and STAT6 KO mice were prime-boost 
immunized with control vaccine (FPV-HIV/VV-HIV). RT-PCR was performed to 
evaluate the IL-17 A regulatory factors in CDS+ T c.ells following HIV-specific 
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(KdGag 197_205) peptide stimulation. Data showed that IL-17A, TGF-~, IL-6 and ROR-yt 
mRNA levels were highly elevated in CD8+ T cells obtained from IL-4 KO mice 
compared to the other groups tested. This data further confirmed that IL-4 played a 
predominant role in down regulating IL-17 A induction, and TGF-~, IL-6 and ROR-yt 
not IL-23a were involved in this regulation. Data also confirmed that GATA3 and T-bet 
did not have any role in regulation of IL-17 A expression in CD8+ T cells. Moreover, the 
granzyme-B expression was lower in IL-4 KO mice compared to IL-13 KO mice, 
indicating that the IL-17 A producing CD8+ T cells in IL-4 KO mice were less cytotoxic 
compared to the IL-13 KO mice. 
As previous studies in our laboratory have shown that IL-13 can significantly modulate 
the avidity of HIV-specific CD8+ T cells, recently, Ranasinghe et al. have developed a 
vaccine that can temporarily inhibit IL-13 at the vaccination site (FPV-HIV IL-
13 Ra2NV -HIV IL-13Ra2) and this vaccine can enhance both the magnitude and 
avidity of HIV-specific CD8+ T cells compared to the control vaccine (FPV-HIV NV-
HIV). Since, IL-4/IL-13 have shown to modulate IL-17A expression, in this study, the 
expression of IL-17 A in HIV specific CD8+ T cells was also evaluated using control 
vaccine and novel IL-13 inhibitor vaccine at 3 days, 14 days, 8 weeks and post-
challenge. Data indicated that compared to the control vaccine, IL-13 inhibitor vaccine 
showed enhanced IL-17 A expression by HIV -specific CD8+ T cells at effector stage and 
following surrogate influenza-HIV mucosal challenge in both spleen and lung. The 
responses following challenge were much greater than at effector stage suggesting that 
IL-17 A expression can be considered as an effective marker of protective immunity. 
Collectively, the data indicate that more than IL-13 IL-4 regulates the IL-7 A expression 
in HIV-specific CD8+ T cells. As IL-4 and IL-13 are involved in regulating the avidity 
of CTLs, IL-1 7 A also plays an indirect role in modulating CD8+ T cell avidity and 
protective immunity . 
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CHAPTER 1: Introduction 
2 
1.1 The Immune system 
The immune syste1n comprises many cells and organs that collectively work together 
interdependently to induce immunity against pathogens. The key function of the 
immune system is based on its ability to distinguish " self' from "non-self' antigens [1]. 
Once the foreign or non-self microorganism is identified, series of immune reactions 
occur to evade the pathogen. The immune system is generally divided into two arms. 
They are 1) the innate immunity, which is non-specific and 2) the adaptive immunity, 
which is specific. 
1.1.1 Innate and Adaptive immunity 
The cells of the innate immune system provide a wider range of protection against non-
specific pathogens. Innate immune system comprises of a physical barrier, complement 
system and a chemical or cellular barrier. The cellular mediators of the innate immune 
system include neutrophils, macrophages, Dendritic Cells (DCs) and Natural Killer 
(NK) cells. Upon encountering an antigen (Ag), these innate immune cells express germ 
line encoded receptors called pathogen recognition receptors (PRRs ), which provide an 
immediate response against the antigen. These receptors identify a unique set of 
structures common to all the pathogens called pathogen associated molecular patterns 
(P AMPs ). P AMPs include a wide variety of structures ranging from all components of 
microbial membranes, cell walls, unmethylated Cytosine phosphate Guanosine (CpG) 
motifs, double stranded Ribonucleic acid ( dsRNA), mannans and reserved structures of 
cell wall. Among the classes of PRRs is the special type of structures called as Toll Like 
receptors (TLRs). The recognition of these TLRs make the innate immune cells capable 
of discriminating self and non-self Ag [2] (Fig 1.1 ). Indeed, these TLRs also act as an 
adjuvant receptors that bridge the innate and the adaptive immune system [3]. 
The adaptive immune response protects the host by providing specjfic, diverse and long 
lasting immunity through immunological memory on subsequent antigenic challenge. 
The adaptive immune response functions through humoral and Cell Mediated Immunity 
(CMI) [4] , [l]. Modulation of different types of adaptive immune response depends on 
various pathways that the DCs mature and present the Ag to the specific cells. Humoral 
immunity refers to the antibody (Ab) mediated immunity against the extracellular 
pathogen. It includes all non-cellular components of the blood such as plasma cells and 
lymphatic fluid . The activation of humoral immune response is initiated by the 
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recognition of Ags by the B cells via immunoglobulins (lg) or B Cell Receptor (BCR), 
which processes and presents the antigen on Major Histocompatibility Complex (MHC) 
class II [ 5]. On the other hand, CMI involves activation of certain subsets of cells 
against the intracellular pathogen such as virus and intracellular bacteria. CMI is 
mediated through CD8+ or CD4+ T lymphocytes, which recognize the antigenic peptide 
in the form of MHC, class I (CD8+ T cells) or MHC class II peptides (CD4+ T cells) 
through T cell receptor (TCR). This recognition further activates B · cells and T cells to 
kill the virally infected target cells. The activation of T cells require two signals i.e. 1) T 
cell receptor (TCR) ligation and 2) simultaneous engagement of CD28 on T cells by 
CD80 and CD86 on the APC [6, 7] (Fig 1.1). These activated T cells become either 
cytotoxic CD8+ T cells (CTL) and CD4+ T cells which are involved in various effector · 
functions of CMI. 
1.1.2 Immunological memory 
The most important aspect of the adaptive immune response is establishing a state of 
immunological memory, which plays a major role in protecting the host from 
reinfection. Thus, obtaining immunological memory becomes a major goal in various 
vaccine strategies. Both memory B and T cells are involved in generating long-term 
-
immunological memory. Memory B cells, in re,sponse to secondary antigenic challenge 
proliferate and differentiate into plasma cells thereby secreting antibody [8-1 O]. The 
antibodies produced by the plasma cells in primary and early secondary response are 
crucial in drivi;ng the B cell maturation. Unlike the B cells, memory T cells are diverse 
in their function and phenotype. T cells are divided into nai:ve, effector and memory 
cells depending on the antigenic challenge. N ai:ve T cells reside in the body before 
encountering of the Ag. -µpon antigenic challenge, these nai:ve T cells become activated 
and tran:sf ormed into effector cell to clear the infection. Once the infection has been 
cleared, Some of these T cells reside in the body as memory lymphocytes to protect the 
host from the same antigenic challenge [ 11]. 
1.2. Thl 7 cells 
Upon TCR mediated activation, nai:ve CD4+ T cells c·an differentiate it?-to four major 
subsets including Thl, Th2, Thl 7, and Treg, which mediate the immune response. Treg 
cells also called as suppressor cells provide tolerance to self-Ag thereby preventing 
autoimmunity .. Thl and Th2 mediate cellular"and humoral immunity by their cytokine 
4 
Fig 1.1 Innate and adaptive immunity 
Innate immunity: Antigen presenting cell such as dendritic cell, 
macrophages recognize antigen (micro-organisms) by TLR (Toll like 
receptor) through P AMPs, which results in non-specific or innate 
immune response. Adaptive immunity: T cells (CD8+ and CD4+ T cells) 
recognize antigen in the form of MHC I and II peptides to mediate 
cytotoxic or humoral inimunity. 
Pathogen . 
reeognitiori .; 
'. '' ' . .' ' . . . ·.· ",' . 
.... :.) . . - ·. . . ·. .:. ·. Patbci.g~a ·o.pt~ke 
~,-;0H like f ' II '~: ,, llilii!IIIIJ!ilill ___ _. and elinJiilntiOO 
profiles [12, 13]. In addition to Thl and Th2 subsets, Thl 7 cells are the newly 
discovered effector CD4+ T cell subsets which specifically produce Interleukin (IL)-
17 A-F (Fig 1.2) [ 14]. These IL-17 A producing cells mediate both innate and adaptive 
arms of the immune response and play a vital role in tissue surveillance especially in the 
gut, lung and skin by inducing early neutrophil recruitment [ 15]. The main sources of 
innate IL-17 producing cells are NK cells, gamma delta (yb) -T cells, lymphoid-tissue 
inducer - like cells and myeloid cells [16-18]. In the context of the adaptive immune 
system, CD4+ and CD8+ T cells are the producers of IL-17 A [19-21]. IL-17, also 
described as CTL associated antigen-8 share a 57% similarity of polypeptide sequence 
to an open reading frame of Herpesvirus saimiri [22-24]. IL-17 family of cytokines 
consists of disulfide-linked homodimeric glycoprotein of 155 amino acids with a 
molecular weight of 35 kiloDalton (kDa) [25 , 26]. There are six IL-17 family members 
IL-l 7A-F [24]. IL-17 cytokines are strongly pro-inflammatory and enhance the 
expression of several chemokines such as Chemokine C-C motif Ligand (CCL2, CCL 7, 
CCL20) [27]. The production of IL-17 has been associated with inflammatory diseases 
and autoimmunity. Interestingly, the IL-17 producing cells are also involved in 
protective immunity (Table 1.1) [21 , 28-44]. 
1.2.1 Differentiation and regulation of Thl, Th2 and Thl 7 cells 
Network of cytokines and transcription factors are crucial in determining the 
differentiation of effector T cell subsets and their cytokine production [ 45]. There are 
different signaling pathways for Th 1, Th2 and Th 1 7 cells (Fig 1. 3) [ 46]. Interferon 
gamma (IFN)-y and Interleukin-2 (IL-2) are the important mediators involved in the 
differentiation of Th 1 cells. IFN-y, signals through signal Transducer and Activation of 
Transcription-I (STATl ) to activate the T-box transcription factor (T-bet) [47, 48] . T-
bet induces IL-1 2 Receptor (R) B2 subunit which together with IL-12RB 1 form IL-12R 
complex. IL-1 2 mediates activation of STAT4 through IL-12R complex and stabilizes 
IFN-y production. 
On the other hand, Th2 cells require TCR with IL-4 mediated signaling to induce 
ST AT6 transcription, thereby promoting the transcription of GA T A3 [ 49]. GA T A3 then 
promotes IL-4 production for the development of Th2 cells. In contrast to Th 1 and Th2 
subsets requiring IFN-y and IL-4 cytokines respectively, Thl 7 cells do not require IL-17 
for its differentiation. It is established that Thl 7 differentiation requires IL-6 and 
5 
Table 1.1 
Pathogen Vaccine · Organ Mechanism/Reference 
M. tuberculosis 1) Peptide vaccine Lung Recruitment of CD4 Thl cells (21) 
2) Subunit vaccine Lung (28) 
3). Viral vectors expressing Lung (40) 
protective antigen 
4) Primary BCG vaccination 
? 
follo"."ed by booster with viral Lung 
vectors expressing protective 
antigens (44) 
5) Primary BCG vaccination (39) 
followed by booster with 
DNA vaccine encoding 
protective antigens 
6) DNA vaccine expressing Lung (36) 
protective antigen and 
S. pneumoniae 
B. pertussis 
H. pylori 
expressing IL-23 
Pneumococcal whole-cell 
antigen 
Cell Wall polysaccharides 
Live organisn1 
Whole cell vaccines 
H. pylori lysate and 
Lung 
Lung 
Lung 
Lung 
Recruitment of neutrophils, 
(33) 
Monocyte, macrophage, and neutrophil recruitment 
and phagocytic killing (35,29) 
Monocyte, macrophage, and neutophil recruitment 
(30) 
N eutrophil recruitment and enhanced phagocytic 
killing ( 4 2) 
killing activity (34) 
recoinbinanturease 
Gut 
P. aeruginosa Live organisin 
Rhesus rotavirus Recoinbinant antigen 
Influenza Virus DNA Vaccine expressing 
protective antigen and IL-23 
Table reproduced froin Lin et al. 2010 (41) 
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Fig 1.2: Thl and Th2 and Thl 7 immune response 
Nai"ve CD4+ T cell through its activation by TCR and antigen presenting 
cell derived co-stimulatory molecules differentiate into different Th 
subsets, such as Thi secreting IFN-y, IL-2 and Th2 secreting IL-4, IL-13, 
IL-10 and Thi 7 secreting IL-1 7 A-F. This differentiation of T cell subsets 
leads to various effector functions in clearing the infection. 
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Transformation Growth Factor-Beta (TGF-~) initially for its development [50]. Using 
IL-6 and TGF-~ transgenic mice, the essential role of these cytokines has been 
illustrated in various studies [51-53]. IL-6, a strong pro-inflammatory cytokine is 
expressed by the cells of the innate immune system on its interaction with specific 
PRRs. TGF-~ being an anti-inflammatory cytokine, through its downstream signaling 
with IL-6 receptors is involved in inducing IL-17 in naYve T cells [54]. TGF-~ is mainly 
involved in inducing Treg transcription factor Fork-head box transcription factor-3 
(Foxp3) for the activation and maintenance of Treg cells in the peripheral immune 
compartment [55 , 56]. Thus, two cytokines (IL-6 and TGF-~) with their opposing 
effects interact with each other to drive the differentiation of Thl 7 cells. The cytokine 
promoters such as IL-6, IL-21 and IL-23 activates STAT3 , which then binds to IL-17 
and IL-21 to further activate Retinoic acid receptor related orphan receptor-yt (ROR-yt), 
inducing the differentiation of Thl 7 [57-59]. Studies have also shown that interferon 
regulatory factor-4 (IRF-4) is also required in the earlier stages of Th 1 7 development 
[60, 61]. 
1.2.2 Cross inhibition of Thl, Th2, Treg and Thl 7 cells 
The differentiation of effector Th subsets involves the cross inhibition of other subset 
and their effector cytokines production [62]. For example, the transcription factor T-bet 
regulates IFN-y production and inhibits the expression of Th2 cytokine by suppressing 
the GA T A3 and IL-4 effector functions [ 63]. In contrast, over expression of GA T A3 
also suppresses T-bet and its effector cytokine production. Similarly, FoxP3 
(transcription factor for Treg cells) and ROR-yt (transcription factor for Thl 7 cells) 
suppress each other during their cytokine differentiation [64, 65]. Indeed, studies have 
shown that inhibiting ROR-yt mediated IL-17 increased the expression FoxP3 [66]. In 
addition, IFN-y, IL-4, IL-13 through their transcription factors T-bet and GATA3 
respectively suppress ROR-yt resulting in the inhibition of IL-17 A production [20, 67] 
(Fig 1.3). Recent studies have also shown that IFN-y deficient mice produce increased 
numbers of IL-17 producing T cells during mycobacterial infection [68]. Furthermore, 
epicutaneous sensitization using IL-13 , IL-4 KO (Gene knock out) and IL-13 IL-4 DKO 
(Double gene knock out) mice also showed exaggerated IL-17 A production in the lung 
resulting in airway inflammation [69]. In a recent study Newcomb et al. have shovm 
that a functional IL-13R is expressed on CD4+Thl 7 cells and IL-13 negatively regulates 
IL-17 production by down-regulating ROR-yt while increasing STAT6 and GATA3 
6 
expression [70, 71]. These studies demonstrate that Th2 and Thl cytokines and their 
transcription factors modulate the function of IL-17 production by T cells. This forms 
the basis of the current project. 
1.2.3 IL-17 family 
IL-17 includes a family of cytokines IL-17 A, IL-17B, IL-17C, IL-17D, IL-17E ( also 
called as IL-25) and IL-17F [24] (Table 1.2, Fig 1.4)[72]. IL-17A and F share a 55 % 
similarity and are produced by a variety of cell types including CD4 +, CD8\ NK cells, 
y6-T cells and also neutrophils [73, 7 4]. IL-1 7 A and F are the key cytokines known for 
activating and recruiting neutrophils to the site of infection [75]. Both IL-17 A and F 
have been shown to mediate autoimmunity and inflammation. IL-1 7B and C have been 
shown to be involved in the transcription of pro-inflammatory genes similar to that of 
IL-17 A and F [76]. Also IL-17D is involved in pro-inflammatory gene expression 
profiles in endothelial cells [77]. In contrast, IL-17E (IL-25) is produced during Th2 
differentiation to induce chemokines such as RANTES and Eotaxin-1 against allergic 
response [78]. IL-25 has also shown to play a protective role in nematode infection by 
recruiting Th2 cytokines (IL-4/IL-5/IL-13) to resolve the infection and also induce 
allergic response in asthma models [79-81]. · IL-17E also inhibits Thl 7 cell 
development through the induction of IL-13 by dendritic cells [82] (Table 1.2) [77]. 
1.2.4 Signaling of IL-17 
It has been shown that IL~ 17 family cytokines signal through the receptors of the IL-
17R family. The IL-17R family consists of IL-17RA, IL-17RB, IL-17RC, IL-17RD and 
IL-17RE. All of these receptors are transmembrane domain containing 499-866 amino 
acids [77]. There is no receptor for lL-1 7F as IL-1 7 A and F share a common receptor 
" ' 
IL-1 7RA, with IL-1 7 A of higher affinity. When binding IL-1 7 A or IL-1 7F, the IL-
17RA processes a conformational change resulting in the dissociation of its intracellular 
domain. IL-17RA and IL-17RC have been involved in the binding of IL-17 A and IL-
1 7F. IL-1 7RB binds. to IL-1 7B and IL-1 7E ( also called as IL-25) and the subunits of 
these receptors are· highly expressed · in endothelial c~lls and Th2 cells. IL-1 7E also 
activates NFATcl (Nuclear factor of activated T ·cells, cytoplasmicl) resulting ,in 
enhanced IL-4 expression by Th2 cells [83]. IL-17RD is involved in the 
proinflammatory activities and its receptors is unknown (Table 1.2). In mammals, IL-17 
exists as the closest homolog to ·similar Expression of Fibroblast growth factor genes 
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Fig.1.3 Regulation of Th subsets 
Differentiation of Thi , Th2 and Thi 7 cells: IFN-y receptor signals 
STAT 1 (Signal transducer and activation of transcription) resulting in 
the activation of T-Bet transcription factor to induce Thi effector 
response. In contrast, IL-4 receptor signals through STAT6, which 
promote GATA-3 transcription to induce the differentiation of Th2 cells. 
iTreg differentiate through the activation of Fox-p3 signal by the 
secretion of TGF-/3. The differentiation of Thi 7 initially requires 
cytokine promoters IL-6, IL-21 and IL-23 to activate STAT3 to induce IL-
21 and IL-23R for Thi 7 induction. Finally, ROR-yt is required for its 
expansion and survival. Fig modified.from Yu et al.2008 [46}. 
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Fig 1.4: IL-17 family-ligand receptors (IL-17R) 
IL-1 7 R family contains IL-1 7 RA, IL-1 7 RB, IL-1 7 RC, IL-1 7 RD and IL-1 7 
RE, which are single transmembrane domain bound receptors consisting 
499-866 amino acids. These various receptor complexes mediate with 
specific ligands to induce the IL-1 7 A signaling. Figure modified from 
Zepp Wu et al. 2011 [72]. 
IL-17E 
IL-17RB IL-17RB 
? 
! 
Act-1 
Th2 cytokines 
IL-17A-F 
IL-17C 
IL-17RA 
IL-17RC IL-17RD 
? 
! 
Act-1 
Cytokines, chemokines, 
Neutrophil recruitment, 
Autoimmunity, 
· inflammation 
and 
HOST DEFENCE 
IL-17D 
IL-17RE 
? 
-Table 1.2: IL-17 family, receptors and functions 
Family Receptors Functions Expression 
member 
IL-17A IL-17RA Autoimmunity Thl 7 cells, CD8+ T cells, 
and IL- and neutrophil NK cells, y6 T cells 
17RC recruitment, 
protective 
immunity 
IL-17B IL-17RB Pro inflammatory Cells of gastrointestinal 
activites tract and pancreas 
IL-17C IL-17RE Pro inflammatory Kidney cells and cells of 
activites prostate 
IL-17D Pro inflammatory Cells of lung, muscles, 
activites brain, heart, pancreas 
IL-17E IL-17RA Induces Th2 Intraepithelial 
and IL- responses and 1 ymphocytes,eosinophils, 
17RB suppresses Th 1 7 basophils, NKT 
cell responses cells, Th2 cells, mast 
cells 
IL-17F IL-17RA Neutrophil Thl 7 cells, CD8+ T cells, 
and IL- recruitment and NK cells,y6 T cells 
17RC immunity to 
extracellular 
pathogens 
Table adapted.from Gaffen et al, 2009 [77} 
(SEF), which acts in inhibiting fibroblast growth factor signaling. The sequence 
homology in the cytoplasmic region of IL-17 family of receptors are also called as 
SEFIR residing in SEF and IL-17Rs domain [72]. Also, adaptor protein Act-1 plays a 
key role in the signaling of IL-17R complex [84]. Act-1 signals IL-17A and IL-17F via 
IL-17RA and IL-1 7RC through SEFIR-SEFIR interactions leading to the recruitment of 
TNF-receptor associate factor-6 (TRAF-6) and TGF-~ activated kinase (TAKI). The 
series of signaling results in the downstream signaling/activation of Nuclear Factor-K~ 
(NF-K~) I Mitogen-activated protein kinase (MAPK) pathways [85] (Fig 1.5). In 
addition, IL-17 has also shown to be involved in the activation Janus Kinase (JAK)-1, 
JAK-2 associated phosphoinositide-3 kinase pathway which act with NF-K~ in 
enhancing gene expression of host defense [86]. 
1.3 Vaccines 
Vaccines have played a crucial role in protecting the humans against deadly diseases 
[87]. The successful application of vaccinia virus to protect against smallpox by Edward 
Jenner represents the beginning of the vaccine era. In general, vaccines mainly function 
by mimicking the infections and providing long lasting memory response that can 
potentially protect the vaccine recipient against subsequent antigenic challenge. Ideally, 
an effective vaccine should provide strong neutralizing antibody responses and T cell 
mediated immunity against the pathogen. The developments of effective vaccines 
against infectious diseases have improved the quality of human life. For example, live 
attenuated viruses, "killed viruses?', subunit and recombinant viruses are used in 
vacci?-es a1:-d were shown to be inducing strong antibody and cell mediated immunity 
against viruses such as polio, small pox [88], hepatitis B, influenza, mumps, measles 
and rubella [89-91]. The development of the recent cervical cancer vaccine has been a 
great succoess [92].. Despite major advances in vaccine development, there are still no 
effective vaccines offering protective immunity against many chronic infections such as 
malaria, Tuberculosis and HIV-1 (Human Immunodeficiency Virus-I). 
1.3.1 HIV-1 vaccines- current status 
Since the discovery of HIV in 1983 [93], HIV-1 has become one of the most 
devastating diseases especially in sub-Saharan Africa. Today, HIV-1 has claimed over 
3 3 million 1eaths worldwide. Three decades 'llave passed and still there is no cure for 
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Fig.1.5: Receptor signaling of IL-17 A and IL-17F 
Upon activation through the signals, Act-I protein interact with SEFIR 
domain of IL-1 7 R complex to activate the transcription factors. This 
series of signaling leads to downstream signaling /activation of NF-K/3 to 
recruit neutrophils. (Fig modified from Zepp Wu et al. 2011 [72]. 
IL-17 A-IL-17F 
IL-17RA and IL-17RC 
Neutrophil 
recruitment 
HIV-1 other than life-long anti-retroviral treatment that can reduce the viral load. The 
main hurdles in developing HIV -1 vaccine are high HIV -1 mutation rates, inability to 
produce broadly neutralizing antibodies and lack of immune correlates of protection in 
humans [94, 95]. Many systemic HIV -1 vaccine strategies that have elicited great 
promise in animal models have failed to induce good protective immunity in human 
clinical trials. For example, the Merck STEP HIV-1 recombinant adenoviral vaccine 
trial conducted in 2007 was unexpectedly terminated due to the failure in inducing 
protection in humans [96]. 
Therefore, there is a great need to understand why these vaccines are failing in humans, 
and evaluate the correlates of protective immunity in humans. In the context of effective 
HIV-1 vaccines, CD8+ T cell mediated immunity and neutralizing antibodies are 
thought to be important in protective immunity [4, 97-101]. Due to the difficulty in 
obtaining immunogens to induce high titer neutralizing antibodies with broad 
specificities, lots of attention has been focused on stimulating HIV -specific T cell 
responses for their ability to better control the viral replication and its association with 
long term survival [102, 103]. 
The development of recombinant DNA (rDNA) immunization in early 1990s offered 
hope for many diseases for which traditional vaccine delivery approaches were 
ineffective. These vaccines showed significant advantages over other immunization 
strategies mainly due to vectors being non-replicative, non-infectious, non-integrating, 
stable and ease of prepare and their lower cost. Fuller et al. were the 1st to demonstrate 
that gene gun delivery of rDNA expressing envelope glycoprotein - gp 120 was able to 
induce both humoral and cellular mediated immunity in small animal models [ 104, 
105]. However, compared to gene gun delivery single or multiple intra muscular (i.m.) , 
or intravenous (i.v.) rDNA delivery strategies were unable to generate comparable 
immune outcomes against highly pathogenic organisms such as HIV-1. Since then 
rDNA vaccines soon became an excellent priming modality in prime boost vaccination 
[106, 107] (Fig 1.6). As boosting vectors, a range of viral vectors that have been used 
for vaccination against HIV-1 include avian poxviruses such as Fowl pox virus (Coupar 
et al. , 2006), mammalian poxvirus vectors for example NewYork Vaccinia virus 
(NYV AC) [108, 109] Modified Vaccinia Ankara (MV A) vectors [11 OJ. Similarly in 
the recent years adenovirus [96, 111 , 112] influenza virus [113] and polio virus [114] 
have also been trialed as vaccine vectors. 
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In mice and macaques, systemic rDNA pnm1ng and recombinant rFPV boost 
immunizations with HIV -1 antigens have elicited high levels of antigen specific T cell 
immunity [115-120]. Similarly, Amara et al. have shown that HIV-DNA prime 
followed by MVA-HIV boost immunization generated protective immunity in 
macaques [ 121]. Despite the success in animal models most of these DNA/viral prime-
boost vaccines have yielded poor outcomes in systemic phase I clinical trials [ 122, 123]. 
Alternatively, viral/protein, viral/viral prime-boost immunization strategies were also 
employed to overcome the poor outcomes with these rDNA vaccines. For example, 
studies in our laboratory have shown that compared to DNA/viral prime-boost 
immunizations pox viral/poxviral prime-boost immunization can generate excellent 
high quality or avidity HIV-specific CD8+ T cell responses [124]. Also, in a recent 
HIV-1 human clinical trial, a recombinant canary pox vector (ALVAC-HIV) prime 
followed by recombinant gp120 subunit vaccine (AIDSVAX B/E) booster 
immunization resulted partial protection against HIV-1 ( vaccine efficacy of 31.2%) 
[ 125]. Interestingly, these vaccines were not successful at inducing good T or B cell 
immunity when used as single modality vaccines. Thus, viral/viral or viral/protein 
prime-boost immunization strategy offers renewed hope for a successful future HIV -1 
. 
vaccine. 
1.3.3 Importance of mucosal immunity and route of immunization 
Although the systemic prime-boost vaccination strategies offer strong T cell response, 
these vaccines have failed to induce protective immunity at the mucosae (i.e. genito-
rectal mucosa). Indeed, HIV-1 is fir~tly encountered at the mucosae and the first CD4+ T 
cell depletion and viral replication occurs predominantly in the gut mucosae (Fig 1. 7) 
[126-128]. Therefore, the expression of strong sustained antiviral CTL responses at 
these mucosal sites is thought to be essential for protective immunity against HIV-1. 
Various studies have demonstrated that mucosal delivery of a vaccine can lead to the 
generation of immunity at both the local and distant mucosae [129, 130], [131]. Studies 
from our laboratory have shown that following pure systemic prime-boost 
immunization FPV-HIVNV-HIV immunization can induce immunity in systemic or 
blood compartment but not long lived 4nmunity in the mucosal compartment [132]. 
This is mainly due to systemic vaccination inducing lower levels of mucosal homing 
markers ( a4~7 and CCR9) on HIV-specific CD8+ T cells that could migrate to the 
mucosae [133-135]. Also, studies by BelyakGv et al. have demonstrated that mucosal 
,, ' 
administration of either peptide or recombinant HIV vaccine can induce strong CTL in 
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Fig 1.6: Prime boost Immunization strategy 
Same vaccine antigens are encoded in two different vaccine vectors (i, e 
rFPV and r VV). Following prime initial T cell subset is induced against 
the encoded antigen and during booster immunizations, these T cell 
responses are expanded. 
PRIME 
VACCINATION 
+ 
T cells specific for 
vaccine antigen · 
BOOST 
VACCINATION 
+ 
Amplification of T cells 
specific to vaccine 
antigen 
Fig 1. 7: Schematic diagram depicting the pathogenesis of HIV 
HIV infects CD4+ T cells and LC of the genital mucosa. Inflammatory 
cytokines and chemokines induce HIV-infected LC, lamina propria DC 
and macrophages to migrate through the lymphatic vessels to the genital 
lymph nodes where the APC pass the HIV infection on to highly 
susceptible CD4+ T cells. Once in the lymph node, the infection rapidly 
expands and disseminates through the lymphatic system to the blood and 
then to all lymphoid tissues. Figure reproduced from Miller et al. 2007 
[128}. 
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the mucosa! compartment [136-138]. Furthermore, Ranasinghe et al. have demonstrated 
that compared to pure systemic (i.m/i.m) and pure mucosa! (i.n/i.n) poxvirus prime-
boost immunization, combined mucosaVsystemic (i.n/i.m) immunization can generate 
robust T cell mediated immune response in both systemic and mucosa! compartments 
[132] (Table 1.3). These studies indicate that route of delivery plays an important role in 
inducing systemic or mucosal immunity. 
1.3.4 Avidity of T cells: 
Many studies have shown that rather than the magnitude (number of IFN-y producing 
HIV- specific T cells), the quality or avidity of T cells plays an important role in 
protective immunity [139-142]. Avidity can be explained as the strength of interaction 
between a T cell and the target antigen or the ability of the T cells to recognize MHC 
complexes on the target cells. In addition, high avidity CTLs recognize low 
concentration of MHC-I peptide complexes when compared to low avidity CTLs which 
are ineffective at recognizing low concentration of peptides on antigen presenting cells 
(Fig 1.8) [139, 143]. This suggests that high affinity CTL clear the viral infections more 
efficiently than the low CTL. 
Studies in our laboratory, have shown that unlike systemic immunization (i.m/i.m), 
mucosal (i.n/i.n) and combined mucosal-systemic (i.n/i.m) immunizations can generate 
high avidity HIV-specific CTLs, where i.n/i.n > i.n/i.m > i.m/i.m (Ranasinghe et al. , 
2007) and the mucosally immunized animals were better protected against the mucosal 
influenza-HIV challenge (Ranasinghe et al. , 2007). Furthermore recent, studies in our 
laboratory also indicate that compared to i.m. DNA-HIV /i.n. FPV -HIV poxvirus prime-
boost immunization, i.n FPV-HIV/ i.m VV-HIV prime-boost vaccine can generate 
elevated high avidity CD8+ T cells, with broader cytokine/chemokine profiles with 
excellent protective immunity [ 124 144]. Belyakov et al. have also demonstrated that 
mucosa! HIV-1 vaccine generates highly functional CD8+ T cells in the gut mucosa 
compared to the systemic immunization, and these high avidity CD8+ T cells are 
efficient at controlling HIV-1 viral replication in macaques [145]. These observations 
clearly indicate that the route of immunization not only influence the magnitude but also 
the quality of immune response. 
The ability of T cells to secrete certain cytokines have shown to be crucial in 
influencing the avidity of CD8+ T cells. For example, high avidity CD8+ T cells are also 
1 1 
Table 1.3: Route of vaccine delivery and magnitude of immune response 
Vaccine delivery route 
Systemic immunization 
(i.m / i.m) 
Mucosal immunization 
(i.n / i.n) 
Combined mucosal and 
systemic immunization 
(i.n / i.m) 
Mucosal response 
Low 
High 
High 
Systemic response 
High 
Low 
High 
BALB/c mzce (n=4-5) were prime boosted with 1) i.n/i.n, 2) i.n/ i.m, 3) i.m/i.m) 
following FPV-HIV VV-HIV (expressing HIV gag pol genes). At 14 days post booster 
immunization, · animals were sacrificed, spleens were harvested and single cell 
suspensions were prepared. Magnitude of systemic CD8+ T cell responses were 
measured by IFN-y EL/spot [144]. 
Fig 1.8: Schematic diagram indicating the role of high and low 
avidity CD8+ T cells 
High avidity CTLs recognize low concentration of MHC I peptides on 
APC and are highly polyfinctional. In contrast, low avidity CTLs usually 
recognize much higher concentrations of MHC I peptides on APC and 
are poorly polyfunctional. 
Highly Polyfunctional and express 
Thl cytokines (IFN-y, TNF-a, IL-2 
Induce rapid viral clearance and 
protective immunity 
Cytolysis 
APC 
Poorly Polyfunctional and 
express elevated Th2 cytokines 
Induce lower protection 
Cytolysis 
AFC 
thought to be multifunctional or polyfunctional and are able to produce range of Thl 
(IFN-y, IL-2 and TNF-a) cytokine upon peptide stimulation [96, 146, 147]. Similarly 
studies also have shown that low avidity CD8+ T cells produce Th2 cytokines and 
become poorly functional (Kienzle et al. , 2004, [144] 
1.4.1 Modulation of HIV-specific CD8+ T cell avidity by IL-4/IL-13 expression 
In general, it is established that CD8+T cells are unable to produce IL-4, however 
Kienzle et al. for the first time demonstrated that under certain in-vitro conditions CD8+ 
T cells could produce IL-4 and influence the T cell avidity [148]. Similarly, IL-4 
expressing CD8+ T cells were also reported following dengue, natural mouse-pox and 
HIV infections [149] (Ranasinghe unpublished data). This atypical expression of IL-
13/IL-4 is most likely an inherent property of these viruses to evade the immune 
system. 
Studies in our laboratory have shown that following recombinant poxvirus prime-boost 
immunization, HIV-specific CD8+ T cells can express Th2 cytokines IL-13 and IL-4 in 
vivo in a vaccine route dependent manner (i.n./i.n. < i.n./i.m. < i.m. I.m.) and the 
expression was inversely correlated with CD8+ T cell avidity (Table 1.4) [144, 150]. 
This data indicated that mucosal vaccination induced high avidity HIV-specific CD8+ T 
cells with lower IL-4/IL-13 with better protective immunity. Using IL-4, IL-13 KO 
mice Ranasinghe et al. have further substantiated that the total absence of IL-13 
enhanced effector and memory CD8+ T cell avidity (Ranasinghe & Ramshaw 2009a) 
and induce better protective immunity (Ranasinghe et al. Submitted-June 2012). These 
studies clearly indicated that designing HIV-1 vaccines that can induce high avidity of T 
cells offer great promise for the future. 
1.4.2 IL-13 receptor and signaling 
The IL-13 receptor system consists of IL-4 receptor alpha (IL-4Ra), and IL-l 3Ral also 
known as Type II receptor complex and IL-13Ra2 ( decoy receptor) and also IL-13Ra2 
soluble receptors. IL-13Ral itself has a low affinity binding to IL-13 which, when 
combined with IL-4Ra forms a highly functional IL-13 receptor that signals via STAT6 
[ 151-154]. In contrast, IL- l 3Ra2 contains only a short cytoplasmic domain and has rio 
known signaling function serving as an IL-13 decoy receptor (Fig l.9)[152]. Typically, 
IL- l 3Ra2 exists as a membrane bound and a soluble form [155]. 
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Table 1.4: Magnitude and avidity of HIV specific CD8+ T cells 
following route of vaccine delivery in BALB/c and IL-13-/- mice 
Vaccine Mice Strain Magnitude of IL-4/IL-13 CTL avi 
delivery route . . response expression 1n 
(IFN-y) HIV specific 
CD8+ Tcells 
i.n/i.n BALB/c Low Low High 
i.n/i.m BALB/c High Medium Medium 
i.m/i.m BALB/c High High Low 
i.n/i.n IL-13-/- Low Absent High 
i.n/i.m IL-13-/- High Absent High 
i.m/i.m IL-13-/- High Absent High 
BALB/c mice (n=4-5) were prime boosted with FPV-HIV/ VV-HIV 
(expressing HIV gag pol genes). At 14 days post booster immunization, 
animals were sacrificed, spleens· were harvested, and single cell 
suspensions were prepared. Magnitude of systemic CD8+T cell responses 
were measured by IFN-y EL/spot, the expression of IL-4 and IL-13 by 
K:'dag191-~05 specific T cells by single cell multiplex RT-PCR and avidity 
of CTL by K:'Gag191-205 specific tetramer dissociation (Ranasinghe et al, 
2009 ). Six weeks post booster immunization protection was evaluated 
following intranasal influenza virus encoding an HIV K:'Gag191-201 
challenge, ( +) indicates th(! level of protection evaluated by weight gain 
or loss. (Table adapted from Ranasinghe & Trivedi, 2010). 
Fig 1.9: IL-13 receptors and signaling pathway 
IL-13 signals through its complex receptor system including IL-4Ra., IL-
l 3Ra.l and IL-l 3Ra.2. IL-4Ra. heterodimerize with IL-l 3Ra.J to form IL-
13 receptor, activating STAT6 transcription. On the other hand, IL-
l 3Ra.2 serves as a decoy receptor and can be soluble or membrane 
bound form. Figure adapted from Tabata et al. 2007 [152}. 
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To enhance the HIV-specific vaccine mediated CD8+ T cell avidity, Ranasinghe et al. 
have recently designed a HIV vaccine, which co-expresses IL-13 soluble receptor IL-
l 3Ra2~ 1 O together with HIV gag/pol to temporarily block IL-13 expression at the 
vaccination site (in this vaccine the exon 10 of the receptor is deleted thus is referred to 
as ~ 10). Using this vaccine in a prime-boost model, they have also shown that it can 
induce high avidity HIV-specific CD8+ T cells with a broader cytokine/chemokine 
profiles with excellent protective immunity compared to the control vaccine (FPV-
HIV NV-HIV) (Ranasinghe et al.-submitted June 2012). Whether the novel vaccine can 
also modulate IL-17 A expression in HIV-specific CD8+ T cells will be investigated in 
this study. 
1.4.3 IL-13 and its link with IL-17 
Recently, many studies have shown that IL-17 A producing Thl 7 cells are involved in 
the pathogenesis of various autoimmune diseases, differentiation and migration of 
neutrophils and also protective immunity against various extracellular infections (Table 
1.1 ). Recent reports have shown that the loss of CD4+ Thl 7 cells in the Gut Associated 
Lymphoid Tissue (GALT) can be associated with the replication of HIV-1 virus and 
therefore considered to play a role in AIDS pathogenesis [156, 157]. Studies by Cruz et 
al. have demonstrated that IFN-y regulates the expression of IL-17 production in CD4+ 
T cells [68]. On the contrary, Newcomb et al. have shown that a functional IL-13 
receptor (IL-13 Ra 1) is expressed on CD4 + Th 1 7 cells and IL-13 negatively regulates 
IL-17 A production by down-regulating ROR-yt while increasing STAT6 and GATA3 
expression [70, 71]. Also, epicutaneous sensitizations of IL-13 , IL-4 KO (Gene knock 
out) and IL-13 IL-4 DKO (Double gene knock out) mice have shown exaggerated IL-
17 A production in the lung [ 69]. In our laboratory, IL-4/IL- l 3 was shown to play an 
important role in HIV-specific CD8+ T cell avidity. However, whether IL-13/IL-4/IFN-y 
can modulate IL-17 A expression in "HIV-specific CD8+ T cells" in a prime-boost 
vaccination model is not known and this forms the basis of this project. 
1.5 Hypothesis, aims and proposed research 
Hypothesis: IL-17 A expression in HIV specific CD8+ T cell_s is mainly IL-4/IL-13 
dependent and not IFN-y and IL-17 A plays an indirect role in modulating CD8+ T cell 
avidity 
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Aims 
Aim 1: To evaluate whether following HIV-1 prime-boost immunization the 
expression of IL-17 A by HIV-specific CD8+ T cells is regulated in an IL-4/IL-
13, STAT6 dependent manner 
Aim 2: To evaluate whether following novel IL-13 inhibitor vaccine; IL-17 A 
plays a direct or indirect role in modulating HIV-specific CD8+ T cell avidity 
and protective immunity. 
Chapter 3: This chapter evaluates whether IL-4, IL-13 and STAT6 play a role in 
modulating IL-17 A expression in HIV-specific CD8+ T cells following FPV-HIV /VV-
HIV prime-boost immunization. IL-4, IL-13 and STAT6 KO mice were used in this 
study and compared with WT BALB/c control mice. 
Chapter 4: This chapter evaluates the expression of IL-17 A at the mRNA level using 
IL-4, IL-13 and STAT6 KO mice compared to WT BALB/c control mice. Following 
FPV-HIV/VV-HIV prime-boost immunization, the regulation of-IL-17A expression was 
assessed with particular focus on transcriptional factors involved in modulating IL-17 A 
production in HIV-specific CD8+ T cells. Production of IFN-y and granzyme-B were 
also investigated as these have shown to dampen or regulate IL-1 7 A and cytotoxicity. 
Chapter 5: This chapter evaluates the modulation of IL-1 7 A by a novel IL-13 inhibitor 
vaccine strategy developed in our laboratory that transiently inhibit IL-13 at the 
vaccination site. Immunizing WT BALB/c mice with novel IL-13 inhibitor vaccine, the 
expressio~ of IL-17A in HIV-specific CD8+ T cells was evaluated at different time 
intervals (acute, effector, memory and following challenge) to establish the involvement 
ofIL-17A in protective immunity. 
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CHAPTER 2: Materials and Methods 
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2.1 Materials 
Table 2.1 
Cell lines Description 
143B cell line (ATCC CRL-8303) Human osteosarcoma cell line 
CV-1 cell line (A TCC CCC-70) African green monkey cell line derived 
from kidney cells 
Table 2.2. 
Buffers/solutions Components Source 
Red cell lysis buffer 0.16 M Ammonium Prepared in the lab 
chloride, 0.17 M Tris HCl 
FACS buffer PBS 950 ml+ Prepared in the lab 
FCS 50 ml 
1 x Intracellular fixation 4o/o Paraformaldehyde + Biolegend 
buff er (IC-FIX) PBS 
1 x Permeabilization buffer 1 Ox permeabilization eBiosciences 
buffer (100 ml)+ 
ddH20 (900 ml) 
FACS sample PBS+ 0.5% Prepared in the lab 
resuspension buff er Paraf ormaldehyde 
Wash buffer PBS+ 0.05%Tween 20 Prepared in the lab 
1 x Brefeldin A solution 1: 1000 dilution in eBiosciences 
(1 OOOx) (BFA) Complete RPMI media 
Tryphan Blue (0.4%) 1 :5 dilution in PBS Invitrogen 
Complete RPMI medium RPMI 1640 GIBCO 
FCS 5% + Invitrogen 
50mMHEPES Invitrogen 
6.5 nM sodium pyruvate Invitrogen 
50 µg/ml Streptomycin Media wash-up 
30 µg/ml Penicillin Media wash-up 
50µM 2- Sigma 
mercaptoethano 1 
Minimal Essential MEM+ GIBCO 
Medium (MEM) FCS 5% Invitrogen 
50 mM HEPES Invitrogen 
50 µg/ml Streptomycin Media wash-up 
3 0 µg/ml Penicillin Media wash-up 
I 50 µM2 Sigma 
mercaptoethano 1 
Lung digestion buffer Complete medium+ 
2 mg/ml Collagenase Sigm3: . 
2.4 mg/ml Dispase GIBCO 
5 U/ml DNAse Calbiochem 
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2.3 Antibodies 
Name Working 
dilution 
Anti CD8 1:300 
APC 
Anti CD8 1:200 
FITC 
Anti CD8 PE 1:1000 
Tetramer 0.3 µI/well 
APC 
Anti-IFNy 1:200 
FITC 
Anti IL-17 1 :100 
APC 
Anti ROR-yt 1:100 
PE 
CD8 cocktail 1 :20 
Biotin 1:10 
cocktail 
Magnetic 1 :20 
nanoparticle 
Mouse IL-17 1 :250-
Capture 
antibody 
Mouse IL-17 1:250 
Detection 
antibody 
* APC= Allophycocyanin, 
Source 
BD 
Pharmingen 
BD 
Pharmingen 
BD 
Pharmingen 
BRF 
(JCSMR) 
eBiosciences 
Bio legend 
eBiosciences/ 
Jomar 
bioscience 
Stem cell 
Stem cell 
Stem cell 
Catalogue 
number 
553035 
553031 
553033 
09/07 
11731182 
506916 
12-6988-
82 
19753 
19753 
19753 
Experimental use 
Binds to CD8 during surface 
staining . intracellular Ill 
cytokine staining 
Binds to CD8, used . Ill 
tetramer staining 
Binds to CD8 during surface 
staining . intracellular Ill 
cytokine staining 
Used in tetramer staining 
Binds to IFN-y during ICS 
Binds to IL-17 during ICS 
Binds to ROR-yt during ICS 
Binds to cell surface Ag CD4, 
CD 1 lb,CD-19, CD-45R, CD-
49b, TERl 19 
Binds to bispecific tetrameric 
antibody complexes 
Binds to the magnetic labeled 
biotin cocktail 
eBiosciences 167175-85 Binds to IL-17 during 
ELispot 
eBiosciences 133-7177- Detects IL-17 bound to 
68 capture antibody 
FITC= Flµoresceine-isothiocyanate, 
PE=Phycoeryther 
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2.4 Reagents used in RNA extraction and cDNA preparation 
Buffers/Reagents Components Source 
(Final 
Concentration) 
TRl Reagent 1 ml for up to Sigma 
1x10 7 cells/ml 
Chloroform 200 µl UNIVAR 
Sx First strand 2 µl Invitrogen 
buffer 
DNase lU/µl Roche 
Superscript III 200 U/µl Invitrogen 
dNTP lOmM Sigma 
Oligo dT 100 µM Sigma 
2x Hotstar Taq Final QIAGEN 
Master mix concentration 
used lx 
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2.2 Methods: 
2.2.1. Recombinant Poxvirus Vaccines 
Recombinant viruses fowl pox (FPV) and vaccinia virus (VV) were used as vaccine 
vectors. The parent recombinant FPV and VV viruses expressing HIV gag/pol genes 
were obtained from Dr. David Boyle and rFPV vaccines were grown in our laboratory 
by Dr. Ronald Jackson [158, 159]. Also, the vaccines FPV-HIV and VV-HIV co-
expressing IL-13Ra2 were constructed by Dr. Ronald Jackson using established 
recombinant pox viral cloning techniques regularly used in the laboratory (Fig 2.1 and 
table 2.5). 
2.2.2 Preparation of recombinant vaccinia virus vaccine (rVV): 
The roller bottles (Coming) were seeded with CV-1 (lx108) cells in MEM media and 
incubated at 3 7°C. Once the cells reached confluency, they were infected with vaccinia 
virus at 0.05 Multiplicity Of Infection [53] in 50 ml of media and incubated for 45 mins. 
Following incubation, 200 ml of MEM media was added and the cells were incubated 
~or further 48-72 hrs at 37°C. To harvest the virus, cells were scraped off from the 
bottles, placed in 50 ml tubes, and centrifuged at 3000 rpm fo~_ 10-15 mins at 4 °C. The 
cell supematants were discarded and the pellets were resuspended in 5 ml PBS per 
roller bottle. Cells were sonicated 3x at 9 V (volts) for 20 secs and 1 ml aliquots were 
prepared and stored at -7 0 ° C. 
2.2.~ Titr~tion of recombinant vaccinia virus vaccine (rVV): 
To determine the virus titer, rVV were titrated using 143B cells. Firstly, 143B cells 
were seeded onto 6 well plates and incubated overnight or until cells reached 80% 
confluency. The rVV virus was serially diluted (10 fold) and 100 µl of each dilution 
was added to 143B cells for 1 lµ-. Following incubation, 2 ml of MEM media was added 
on to each well and the cells were further incubated for 48 hrs. The media was removed 
and the cells were stained with 0.1 % crystal violet in 20% ethanol to visualize the 
plaques. The plaques were then counted and the titer of the virus stock was determined. 
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Fig 2.1: Schematic diagram of recombinant fowl-pox and vaccinia virus 
. 
vaccines 
Fig a) represents control vaccine encoding HIV gag/pol genes and Fig b) 
represents IL-13 Inhibitor vaccine co-expressing HIV gag/pol genes and 
soluble IL-13Ra2. 
Fig a) Control vaccine 
HIV gag pol 
"F"region 
Fig b) Novel IL-13 inhibitor vaccine 
"F"region 
sz 
Hind III F region 
HIV gag pol 
sz 
Tk 
Tk 
s:z 
Tk 
Table 2.5: Lists of recombinant viruses and their gene insertion sites 
(Coupar et al, 2006) 
Recombinant viruses Insertion sites 
F Region Tk-ORFX or Tk 
FPV-HIV (086) gag / pol 
VV-HIV (336) gag I pol 
FPV - HIV IL-l 3Ra2 gag I pol IL-l 3Ra2 
VV-HIV IL-l 3Ra2 IL-l 3Ra2 gag I pol 
Tk=Thymidine Kinase, ORFX Uncharacterized gene 
2.2.4 Immunization of mice 
Pathogen free, 6-8 weeks old female wild type BALB/c (H-2d), IL-13-/-, IL-4 -/- and 
STAT6-/- knock out mice (KO) on BALB/c background were obtained from the 
Australian National University (ANU) animal breeding facility. These animals were 
used and maintained in accordance with the ANU animal experimentation ethics 
guidelines (Table 2.6). For challenge studies, spleen and lung samples were obtained 
from Dr. Charani Ranasinghe. The weights of unimmunized and immunized animals 
were similar to that observed in Ranasinghe et al.2011 [124]. 
Mice (n=5-10) were prime-boost immunized with either 1 x 107 pfu FPV-HIV or FPV-
HIV IL-13Ra2 followed by 1 x 107 pfu VV-HIV or VV-HIV IL-13Ra2, 2 weeks apart 
using i.n/i.m ( combined mucosal systemic immunization route). 
During intranasal immunization (i.n), mice were anaesthetized under methoxyflourane 
and -10 µl of virus was delivered to each nostril (total not exceeding 25 µl). For 
intramuscular immunization (i.m), mice were first injected intra-peritoneally (LP.) with 
200 µl of avertin (Fluka) as a general anesthetic and mice were then immunized with 50 
µl per leg ( quadriceps muscle) of respective vaccines. 
Following prime-boost immunizations, mice were sacrificed at different time intervals 
(3 days, 14 days, 8 weeks, challenge) and systemic and mucosal T cell response were 
measured in spleen and lung samples respectively (Fig 2.2). 
2.2.5 Peptides used: 
In intracellular . staining, ELispot and RT-PCR assays, cells were stimulated with 
immunodominant H-2Kd binding 9 mer HIV Gag peptide 197AMQMLKETI205 , 
synthesized at the Biomolecular research facility (BRF), JCSMR. 
2.2.6 Preparation of splenic lymphocytes: 
To evaluate systemic T cell responses in spleens at acute, effector and memory stages of 
immune response, mice _were sacrificed at 3 days, 14 days and 8 weeks following prime 
boost immunization respectively (Fig 2.2). Single cell suspensions of spleen sampJes 
. were prepared by passing spleen through Falcon TM Nylon cell strainer into RPMI 
medium (Table 2.2) using a syringe plunger. Cells were then washed and resuspended 
in red cell lysis buffer for 5-7 mins at room temperature. 'Cells were diluted with 20 ml 
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Fig 2.2: Vaccination-time line: 
Schematic diagram of the vaccines used and the time schedule. 
2 weeks 3 days 14 days 8 weeks 10 days 
• • • • \II l 0 
. 
. 1.n •~m 
Ix 107 PFU Ix 107 PFU 
rFPV-HIV (or) rVV-HIV (or) 
. r FPV-HIV-IL-13Ra2 rVV-HIV-IL-13Ra2 
Table 2.6: List of mice and vaccines that were used in this study 
Mice Vaccines 
Prime Boost 
BALB/c FPV-HIV VV-HIV 
BALB/c FPV-HIV IL-13Ra2 VV-HIV IL-13Ra2 
IL-13 KO FPV-HIV VV-HIV 
IL-4 KO FPV-HIV VV-HIV 
STAT-6 KO FPV-HIV VV-HIV 
HIV= gag pol genes 
FPV = Fowl pox virus 
VV = Vaccinia virus 
IL-l 3Ra2 = IL-13 Soluble receptor 
of RPMI media and were centrifuged at 1200 rpm for 5 mins at 4°C. Cells were then 
washed twice in RPMI medium. Cell pellets were resuspended in a final volume of 5 ml 
complete RPMI medium, and were counted using Neubauer haemocytometer. 
2.2. 7 Preparation of lung samples: 
Lung samples were cut into small pieces and digested with 1-2 ml of lung digestion 
buffer as described in table 2.2. The samples were then incubated at 37°C in a water 
bath for 1 hr with gentle vortexing every 15 mins. The digested cell suspensions were 
passed through a Falcon TM Nylon cell strainer into RPMI medium. Cells were then 
resuspended in red cell lysis buffer for 5-7 mins at room temperature, samples were 
diluted with RPMI medium and were centrifuged at 1200 rpm for 5 mins at 4°C. The 
samples were then filtered through sterile gauze to remove connective tissue and debris. 
Following filtration, the samples were washed twice in complete RPMI and the cell 
pellets were resuspended in 1-2 ml of complete RPMI and the cells were counted. 
2.2.8 Tetramer staining 
Tetramer staining was performed to evaluate the number of HIV-specific CD8+ T cells. 
2 x 106 cells were added into 96 well U-bottom plates and were washed with 100 µl 
F ACS buffer. Diluted fluorescein isothiocynate (FITC) conjugated anti CD8 antibody 
(1 :200 final dilution) and 0.3 µl of APC labeled Gag 197 AMQMLKETI205 H-2Kd 
restricted tetramer (synthesized at the BRF-JCSMR) was added at a final volume of 40 
µl, and cells were incubated at room temperature in the dark for 45 mins. Following 
incubation, cells were washed twice and resuspended in 100 µl of F ACS buffer. 
Tetramer specific CD8+ T cells were sorted using FACS LSR ARIA-II. 
2.2.9 Intracellular Cytokine Staining of IFN-y and IL-17: 
For intra_cellular cytokine staining, 4 x 106 cells/well were aliquoted into a 96 well U 
bottom plates and stimulated with.immunodominant H-2Kd binding 197 AMQMLKETI205 
9 mer Gag peptide (5 µg/ml of fmal concentration) for 16 hrs at 37 °C with 5% CO2• 
Brefeldin-A (1: 1000 (1 OOOx stock) was added and the -samples were further incubated 
for 4-5 hrs. Cells were washed with F ACS buffer and firstly stained with anti-CD8 PE 
(1: 1000 dilution) (B.D Pharmingen) diluted in F ACS buffer and incubated for 30 mins 
at 4 °C. Unbound antibodies were removed by washing with F ACS buffer and cells were 
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then fixed with 100 µl of lx IC -FIX for 10 mins on ice. Cells were then washed and 
permeabilized by re suspending in 100 µl IC-PERM for 10 mins at room temperature. 
Cells were spun down and conjugated anti-cytokine antibodies were diluted in IC-
PERM (IFN-y FITC 1:200 and IL-17 APC 1: 100). Cells were then resuspended in 25 
µl diluted antibodies, and incubated on ice for 30 mins. Then, the cells were washed 
twice with F ACS buffer, resuspended in 100 µl of 0.5% paraformaldehyde and were 
transferred to cluster tubes (Costar). Samples were run on a four color F ACS Calibur 
Flow cytometer (Becton and Dickinson) until 500,000 events were acquired. Data were 
analyzed using Cell Quest software using the gating strategy as described in Chapter 3. 
The percentages of the HIV-specific CD8 cytokine producing T cells were calculated by 
subtracting the stimulated values from the unstimulated background. 
2.2.10 Negative selection of CDS+ T cell 
To enrich CD8+ T cell, single cell suspensions of spleen cells were prepared as 
described previously (section 2.2.6). Negative selection was performed according to the 
manufacturers instructions (stem cell). Cell densities were adjusted to 1 x 108 cells/ml in 
PBS supplemented with 1 o/o FCS. The cells were then transferred to 5 ml Falcon™ 
polysterene round bottom tubes. To each tube, CD8 T cell enrichment cocktail (1 :20 
dilution) was added and incubated at 4 °C for 15 mins. Following incubation, Biotin 
selection cocktail (1: 10 dilution) was added, mixed and incubated at 4 °C for 15 mins. 
Magnetic nanoparticles were mixed thoroughly to ensure uniform suspension and was 
added (1 :20 dilution) to the samples and further incubated at 4 °C for 15 mins. The cell 
suspensions were made up to 2.5 ml with FACS buffer. The samples were mixed and 
placed in the Easysep Magnet (Stem cell) for 5 mins. Following incubation, cells were 
collected in a fresh 5 ml polysterene tubes while the magnetically labeled unwanted 
cells remained bound to the original tube by the magnetic field. Isolated CD8+ T cells 
were pooled, washed and resuspended in complete RPMI medium. Both enriched and 
non-enriched samples were surface stained and were analyzed using F ACS calibur for 
purity (Fig 2.3). 
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2.2.11 IL-17A (Enzyme Linked ImmunoSPOT) ELispot 
Spleen and lung cells were assayed for IL-17 A expression by HIV Gag-specific CD8+ T 
cells as described by manufacturer (e-Biosciences). Briefly, Multiscreen PVDF filter 
plates (Millipore, USA) were coated overnight at 4 °C with 4 µg/ml concentration (50 
µI/well) of anti-mouse IL-17 capture antibody. The plates were washed 3x with PBS 
with 0.05% Tween (PBST) and 2x with PBS, and then 200 µl of complete RPMI 
medium was added to each well and the plates were incubated at 37°C for 1 hr with 5% 
CO2• To measure HIV-specific responses, enriched spleen cells and non-enriched lung 
cells at a density of 4 x 106 cells/ml in 100 µl were added to the plates in duplicates. 
Cells were then stimulated with (5 µg/ml) immunodominant H-2Kd binding 
197 AMQMLKETI205 9 mer Gag or with (5 µg/ml) Con-A as a positive control. 
Unstimulated cells were included as negative control. The plates were then incubated at 
37°C with 5% CO2 for 20-22 hrs. The cells were then removed from the plate and to 
lyse any remaining cells, 200 µl of ice-cold ddH20 was added to each well for 10 mins 
then washed 3x with PBST and 2x with PBS. To each well, 2 µg/ml of biotinylated anti-
mouse IL-17 antibody in assay diluent ( 1 x,eBiosciences) was added and the plates were 
incubated at room temperature for 2 hrs. The plates were washed as before and 
streptavidin alkaline phosphatase ( 1 : 1000) (GE Healthcare) was added and incubated 
for 90 mins at room temperature. The plates were again washed and 50 µI/well of 
BCIP/NBT alkaline phosphatase substrate (Moss Inc, USA) was added and incubated 
for 20-30 mins to develop the Spot forming units (SFU). The plates were finally washed 
under tap water and were allowed to dry. The SFU were counted using ELI spot 
Bioreader-4000 PRO-X (BioSys, Germany). 
2.3. Molecular techniques 
2.3.1 RNA isolation 
Spleen cells were counted and CD8+ T cells were enriched as described in 2.2.10. 
Samples were stimulated with 5 · µg/ml immunodominant H-2Kd binding 
197AMQMLKETI205 , 9 mer Gag peptide for 4 hrs and 16 hrs respectively. Following 
stimulation, cells were gently aliquoted into RN ase free eppendorf tubes and were 
centrifuged for 5 mins at 1500 rpm. The supematants were removed and cell pellets 
were snap frozen on dry ice and stored at -70°C until use or 1 ml of TRI reagent was 
added to the cell pellet and were mixed by pipetting several times to break the cells 
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Fig 2.3: CD8+ T cell enrichment 
Spleen cells were harvested from BALB/c mice and single cells suspensions 
of spleen cells were prepared. CD8+ T cells were enriched as explained in 
section 2. 2.10. 2 x 106 cells of both enriched and non-enriched samples 
were surface stained with anti CD8 APC and anti CD4 FIT C and the 
samples were run in FACS calibur and analyzed using cell quest software. 
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(Table 2.4). Then, the samples were incubated on ice for 15 m1ns and 200 µl of 
chloroform was added into each tube, mixed and further incubated on ice for 15 mins. 
The samples were then centrifuged at 12000 rpm for 15-30 mins at 4°C (Microfuge 
centrifuge, Beckman Coulter), after which the top aqueous phase was removed carefully 
from each sample and transferred into fresh tubes and equal volume of isopropanol was 
added, mixed and the samples were snap frozen on dry ice for 30 mins. The samples 
were centrifuged at 8000 rpm for 30 mins at 4 °C to pellet the RNA. Finally, the 
supematants were removed and pellets were washed in 500 µl of 75% ethanol. The 
pellets were air-dried and resuspended in 20 µl of RNase free ddH20, and stored at -
10°c. 
2.3.2 DNAse treatment and cDNA synthesis 
For the reverse transcription of RNA into cDNA, the frozen RNA samples were 
quantitated using NanodropR ND 1000 Spectrophotometer software. Then the RNA 
samples were treated with DNAse-I (Roche) to degrade the contaminating DNA. For 
each 1-3 µg of RNA, 1 µl of DNase (1 U/µl) and 2 µl of 5x first strand buffer was 
added and mixed gently. Samples were first incubated at 37°C for 30 mins, spun down 
again and further incubated at 75°C for 5 mins to degrade DNase I enzyme. 
The samples were quantitated as before using Nanodrop to obtain the real concentration 
of RNA. For each reverse transcription reaction, 1-3 µg of RNA and ddH20 to a total of 
10 µl was aliquoted into eppendorf tubes and 1 µl of oligo dT primer ( 100 µM) , 1 µl 
dNTP (containing 10 mM each of dATP, dGTP, dCTP, and dTTP) and 3 µl RNase free 
ddH20 was added. Samples were then incubated at 65°C for 5 mins to remove the 
secondary RNA structure and then the samples were spun down, cooled on ice for 2 
mins and to each cDNA synthesis reaction, 2 µl of 5x first strand buffer~ 2 µl of DTT 
(O. lM), and 1 µl superscript III reverse transcription enzyme was added. Samples were 
mixed and then incubated first at 50°C for 50 mins, and then 70°C for 15 mins to 
inactivate the superscript enzyme (Table 2.4). 
2.3.3 Pre-amplification of cDNA 
As the expressions of the cytokines of interests (IL-6, IL-17 IL-23a) and transcription 
factors (T-bet TGF-~ GATA-3 and ROR-yt) were found ·· to be lower where 
appropriate the samples were pre-amplified with gene specific primers using Hot-star 
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Taq Master mix (Table 2.7) [144, 160]. Briefly, 5 µl of Hot-star Taq Master mix, 3 
pmol of each of forward and reverse primer and 1 µl of the synthesized cDNA was 
mixed and the samples were amplified at 95°C for 2 mins followed by 18 cycles of 
95°C for 15 sec and 60°C for 4 mins. The pre-amplified cDNA was diluted 1 :5 and 2 µl 
of the diluted sample was used in real time PCR. 
2.3.4 Real time PCR 
Real-time PCR was performed, using Applied Bio-systems SYBR Green PCR master 
mix (containing SYBR green 1 Dye, AmpliTaq Gold® DNA polymerase, dNTPs with 
dUTP, passive reference ROX™ and buffer). Reactions were performed in eppendorf 
twin-tee 380 well PCR plates in 10 µl reaction volume containing 5 µl master mix, 3 
pmol of each forward and reverse primer and 2 µl of preamplified cDNA. All primers 
were designed to have Tm of 60°C and the reactions were run at lx 50°C for 2 mins, 1 x 
95°C for 10 mins, followed by 40 cycles of 95°C for 15 secs, 60°C for 1 minute on an 
ABI PRISM Q 7900 sequence detection system (Applied Bio systems) and analyzed 
using SDS 1.9.1 software. Fold increase in mRNA were calculated after normalizing 
against house keeping gene; L32 expression, using the formula described in [144]. 
(-MCt) ·-
Fold change= 2 , where ~~Ct= (Ct target-Ct reference) stimulated -
( Ct target-Ct reference) unstimulated 
arbitrary copy numbers were calculated using the formula as described in [161] 
ar~itrary .copy number= (105/2(Ct-I 7)) x 104, where 1 Ct value= 105 mRNA copies. 
The specificity of the real time product was analyzed by performing dissociation curves 
at 95°C for 15 seconds, 60°C for 20 seconds followed 95°C for 20 mins during which 
the dissociation data was collected. The specificity of the product amplification was 
indirectly assessed by the analysis of dissociation curves (Fig 2.4). 
2.3.5 Synthesis of cDNA from tetramer specific CD8+ T cells: 
To examine the mRNA expression profiles IFN-y, IL~l 7, granzyme-B, by HIV-specific 
CD8+ T cell using real time PCR was performed on Kd Gag 197 ... 205 specific CD8+ T cells. 
Firstly, spleen cells from each group were . pooled and KdGag197_205 specific tetramer 
staining was performed as described in 2.2.8. 96 well plates were prepared as follows, 
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Fig 2.4: Dissociation curves and standard curves for qPCR with specific 
. prrmers 
The figures illustrate the dissociation curves of specific primers such as IL-
6, IL-1 7A, IL-23a, T-bet, GATA3, ROR-yt. The peak in the melting curve 
represent melting temperature of each primer and y-axis indicates 
derivative or reaction data, which is the rate of change in fluorescence. 
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to each well 20 µl of cDNA synthesizing buffer containing cDNA buffer 
( 1 x,QIAGEN), 0.5 mM dNTP (QIAGEN), 125 ng oligo dT (promega, USA), SU 
RNasin (Promega), 0.5 nM spermidine (Sigma), 0.1 o/o triton-X 100 (sigma), 0.125 µl 
Sensiscript Reverse Transcriptase (Sensiscript RT kit, QIAGEN) and RNase free water 
was added. KdGag 197_205 specific CD8+ T cells (500 cells/well) were sorted in to the 
above plate using FACS Aria II cell sorter. To synthesize cDNA, the plates were then 
centrifuged at 2500 rpm for 3 mins to break open the cells and were immediately 
incubated at 3 7°C for 110 mins. The plates were then stored at -20°C until further use. 
2.3.6 Pre-amplification and real time PCR on tetramer specific CD8+ T cells: 
To quantify the expression of specific genes in the samples, pre-amplification of cDNA 
and real time PCR were performed as explained previously in section 2.3.3 and 2.3.4 
and the samples were analyzed using SDS software and the arbitrary copy numbers 
were calculated as before. 
2.4 Analysis of data and statistics 
When plotting ELispot and JCS data, the unstimulated values were subtracted from the 
stimulated values except for transcription factor analysis. Experiments were repeated at 
least three times. To obtain statistics, student's two-tailed paired or unpaired t-Test was 
performed. Where possible, data from all the repeated experiments were pooled ( when 
plotting graphs) and mean and standard errors of the mean (SEM) and p values were 
calculated respectively. When plotting Real-time data, mRNA copy numbers were 
calculated from stimulated samples and fold change was calculated by subtracting the 
stimulated values from unstimulated background. All experiments were repeated twice 
and data represented are representative of repeat experiments. 
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Table 2. 7: Primers used in Real time PCR 
Primer Sense primer sequence 5'-3' Anti-sense primer sequence 5'-3' Reference 
IFN-y ATGAACGCTACACACTGCATC AACAGCTGGTGGACCACTC (Ranasinghe et al., 2007) 
IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA (Ranasinghe et al., 2007) 
IL-l 7A TCCAGAAGGcccrcAGACTA AGCATCTTCTCGACCCTGAA (Lexberg et al., 2008) 
0 
IL-23A TGGCTGTGCCTAGGAGTAG AGATGCCCAGCCTGAGTTCT 
Granzyme-B CCACTCTCGACCCTACATGG GATCCTTCTGTACTGTCAGCT (Ranasinghe et al. , 2007) 
ROR-yt TGCAAGACTCATCGACAAGG AGGGGATTCAACATCAGTGC (Lexberg et al., 2008) 
GATA3 CCTACCGGGTTCGGATGTAAGT AGTTCGCGCAGGATGTCC (Lexberg et al., 2008) 
T-bet TCCTGCAGTCTCTCCACAAGT CAGCTGAGTGATCTCTGCGT (Lexberg et al., 2008) 
I . TGF-~ CGTGGAAATCAACGGG CAGAAGTTGGCATGGT (Lexberg et al., 2008) 
i 
L32 GCTGGAGGTGCTGCTGATGTG CGTTGGGATTGGTGACTCTGATGG (Ranasinghe et al. , 2007) 

CHAPTER 3: Elucidate the role of IL-4/IL-13 and STAT6 in 
modulating IL-17A expressions in HIV-specific CD8+T cells 
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3.1 Introduction: 
Developing vaccines to elicit strong sustained cellular immune responses against HIV-1 
has been a challenging task. Even though true correlates of HIV -specific protective 
immunity in humans are not well understood, it is well established that strong CTL 
immunity is important for effective HIV-I virus clearance [1162]. Currently, a body of 
evidence suggests that durability, breadth of response, avidity and cytokine expression 
profile of CTL play an important role in HIV -1 protective immunity [ 163]. 
Interestingly, several studies have indicated that multifunctional CTL that express 
cytokines such as IFN-y, TNF-a and IL-2 are higher in avidity and are a hallmark of 
protective immunity [139, 146, 164]. In our laboratory, Ranasinghe et al. have shown 
that the magnitude of T cell measured by IFN-y production and avidity of CTL vary 
according to the routes of vaccine delivery [132, 144]. They have demonstrated that i) 
mucosal poxvirus prime-boost immunization (i.n/i.n or i.n/i.m) can generate high 
avidity CDS+ T cells compared to pure systemic immunization (i.m/i.m), ii) Systemic 
immunization induce KdGag191-2os specific CDS+ T cells that express elevated Th2 
cytokines IL-13 and IL-4 and these cytokines are inversely correlated with CDS+ T cell 
avidity [144, 150], iii) Using IL-4-/-, IL-13-/- gene knock out (GKO) mice, they have 
further substantiated that IL-4 and IL-13 plays an important role in modulating T cell 
avidity [ 165]. 
Recent studies by He et al. have shown that IL-4 and IL-13 producing CD4 + T cells 
negatively regulate IL-17A [69-71]. In another study, Newcomb et al. have shown that 
CD4+Thl 7 cells, express a functional IL-13Ral and IL-13 negatively regulates the 
expression of IL-17 A by these T cells [166]. On the contrary, Harrington et al. have 
suggested that IFN-y can also negatively regulate Thl 7 cell differentiation and 
proliferation [ 167] . Also, in an IFN-y deficient mouse model, it has been shown that the 
expression of IL-1 7 was enhanced [ 68, 168]. Interestingly, the expression of IL-17 A has 
been implicated in protective immunity [169, 170]. Therefore, in this study we have 
investigated how IL-4, IL-13 and IFN-y are involved in the regulation of IL-17 A 
expression by HIV -specific CDS+ T cells and whether IL-17 A plays a direct or indirect 
' 
role in modulating HIV-specific CDS+ T cell avidity and protective immunity. 
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3.2. Evaluation of IFN-y and IL-17 A expression by HIV specific CD8+ T cells in 
spleen: 
Firstly, intracellular cytokine staining was performed to assess the background splenic 
expression of IFN-y and IL-17 A by the CD8+ T cells in naive wild type BALB/c and 
KO mice. Cells were stimulated with KdGag191-2os peptide for 16-20 hrs, following ICS, 
samples were run on F ACS calibur flow cytometer and 500,000-gated events were 
acquired. Data were analyzed using Cell Quest Pro analysis software using the gating 
strategy indicated in Fig 3.la. The results clearly indicated that in naYve BALB/c, or the 
GKO mice, there was no IFN-y or IL-17 A expression by the CD8+ T cells following 
KdGag197_205 peptide stimulation (Fig 3 .1 a and 3 .1 b ). 
Following vaccination, induction of IFN-y is often considered as a measurement of 
effective immunity. Therefore, in this study, firstly, the expression of IFN-y by 
KdGag197_205 specific CD8+ T cells was evaluated. Results indicated that the expression 
of IFN-y was higher in IL-4-/- compared to wild type BALB/c mice (p = 0.020) (Fig 
3 .2). In addition, no significant difference in IFN-y expression was observed between 
BALB/c, IL-13-/- and STAT6-/- mice, which is consistent with previous finding [165]. 
Similarly, to determine whether IL-4, IL-13 and STAT6 or IFN-=y down regulate IL-17A 
expressing CD8+ T cells, IL-4-/-, IL-13-/- and STAT6-/- mice were prime-boost 
immunized as described previously and the IL-1 7 A expression was evaluated. Results 
indicated that the expression of IL-17 A by the splenic CD8+ T cells in IL-13-/-, IL-4-/-
and STAT6-/- mice were significantly higher as compared to the wild type BALB/c 
control mice (Fig 3.3). The expression profile of IL-17A was IL-4-/- > IL-13-/- > 
. . 
STAT6-/- > BALB/c. 
The muli!ifunctioriality of CD8+ T · cells ;as also investigated to see whether CD8+ T 
cells produce both IL-17 A and IFN-y. Results indicate that in spleen, CD8+ T cells that 
expressed elevated levels of IL-1 7 A also expressed IFN-y in IL-13-/-, IL-4-/- and 
STAT6-/- mice compare to wild type BALB/c control mice. The expression profile of 
these double-.positive CD8+ T cells populations were found to be IL-4 -/- > IL-13-/- > 
STAT6-/- > BALB/c (Fig 3.4). This clearly indicated that, most of the" CD8+ T cells 
expressing IL-17A-in IL-13-/-, IL-4-/- and STAT6-/- mice were also positive for IFN-y. 
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Fig 3.1: Evaluation of IFN-y and IL-17 A expression in naive BALB/c, 
IL-13-/-, IL-4-/- and STAT6-/- mice 
Unimmunized BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) 
mice, splenocytes were prepared as described in materials and methods. 4 x 
106 cells were stimulated with I<1Gag191-2os peptide for 16-20 hrs in the 
presence of brefeldin-A. IFN-y (fig 3.la) and IL-1 7A (fig 3.lb) expressions 
were assessed by intracellular cytokine staining. Unstin1ulated cells from 
each sample were used as a background controls. Gating strategy used in 
flow-cytometric analysis: i) RI indicate the gated lymphocyte population 
using forward scatter and side scatter, ii) R2 represent total CD8+ T cells, 
iii) R3 represent RI + R2. 
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Fig 3.2: Evaluation of IFN-y expression by HIV-specific CD8+ T cells following 
i.n/i.m FPV-HIVNV-HIV prime-boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mzce were prime-boost 
immunized with FPV-HIVIVV-HIV (control vaccine). Splenocytes were prepared as 
described in materials and methods and 4 x 106 cells were stimulated v.1ith K!1Gag197_205 
peptide for 16-20 hrs in the presence of brefeldin-A to evaluate IFN-y expression by 
intracellular cytokine staining. Unstimulated cells from each sample were used as 
background controls. The FA CS plots show representative animals from each group. a) 
In all FACS plots the upper right quadrant (R3) indicates gates RI + R2 (see fig 3.1) and 
the numbers indicate the percentage of CD8+ T cells producing IFN-y. b) The graph 
indicates the percentage of CD8+ T cells expressing IFN-y in each group from n=6 mice. 
In all graphs, unstimulated cells were used as background controls and were subtracted 
from each sample before plotting the data. Data are representative of four independent 
experiments and error bars represent standard error of the mean (SEM). p values were 
calculated using student 's two tailed paired t test *p=O. 020 (BALB/c Vs. IL-4-/-) 
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Fig 3.3: Evaluation of IL-17 A expression by HIV-specific CD8+ T 
cells following i.n/i.m FPV-HIVNV-HIV prime-boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice were 
prime-boost immunized with FPV-HJVIVV-HIV (control vaccine). At 14 
days post booster immunization, splenocytes were prepared as described 
in materials and methods and 4 x 106 cells were stimulated with 
K:'Gag197-205 peptide for 16-20 hrs in the presence of brefeldin-A and IL-
17 A expression was evaluated by intracellular cytokine staining. 
Unstimulated cellsfrom each sample were used as background controls. 
a) The FACS plots indicate representative animals from each group. In 
all FACS plots, the upper right quadrant (R3) indicates gates RI +R2 and 
the numbers indicate IL-17 A producing CD8+ T cells as a percentage 
(top) and the number of events (bottom) within brackets. b) The graph 
indicates the percentage of CD8+ T cells expressing IL-17 A in each of the 
4 groups from n=4 mice/group and data represent mean of three 
independent experiments (n= 12 mice/group). In all graphs, unstimulated 
cells were used as a background controls and were subtracted from each 
sample before plotting the data. The error bars represent standard error 
of the mean (SEM). p values were calculated using student 's two tailed 
unpairedttest *p=0.01 7 (BALB/c Vs. lL-13-/-), **p=0.001 (BALB/c Vs. 
IL-4-/-) and ***p=O. 005 (BALB/c Vs. STAT6-/-). 
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Fig 3.4: Evaluation of IL-17A+IFN-y+ (double positive) HIV-specific 
CD8+ T cells following i.n/i.m FPV-HIVNV-HIV prime-boost 
immunization 
BALB/c, JL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) were prime-boost 
immunized with FPV-HIVIVV-HIV (control vaccine). At 14 days post 
booster immunization, splenocytes were prepared as described in materials 
and methods and 4 x 106 cells were added and stimulated with KGag191-2os 
peptide for 16-20 hrs in the presence of brefeldin-A and IL-17 and IFN-y 
expression was measured by intracellular cytokine staining. Unstimulated 
cells from each sample were used as background control. a) The FACS 
plots indicate representative animals from each group. In all FACS plots, 
the upper right quadrant (R3) indicates gates RI+ R2 and the numbers in 
the upper right quadrant indicate the percentage of CD8+ T cells producing 
IL-1 7 A and IFN-y. Also, the numbers in the upper left quadrant indicate the 
percentage of CD8+ IL-17 A+ and the numbers in the lower right quadrant 
represents the percentage of CD8+ IFN-y+. b) The graph indicates the 
percentage of CD8+ T cells expressing IL-17A in each of the 4 groups from 
n=4 mice/group and data represent mean of three independent experiments 
(n = 12 mice/group). Data represents mean of three independent 
experiments. In all graphs, unstimulated cells were used as a background 
controls and were subtracted from each sample before plotting the data. 
The error bars represent standard error of the mean (SEM). p values were 
calculated using student 's two tailed unpaired t test *p=O. 058 (BALB/c Vs. 
IL-13-/-) , **p=0.001 (BALB/c Vs. IL-4-/-) and ***p=0.004 (BALB/c Vs. 
STAT6-/-) . 
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3.3 Evaluation of IL-17 A expression by KdGag191-2os specific splenic CD8+ T cells 
using ELispot: 
Next, the total number of CD8+ T cells producing IL-17A was also evaluated using 
ELispot. As the number of CD8+ T cells expressing IL-17 was relatively low, CD8+ T 
cells were negatively enriched and IL-17 A expression was further evaluated. Results 
showed the expression of IL-17 SFU were higher in IL-13-/-, IL-4-/- and STAT6-/-
animals compared to wild type BALB/c control mice (Fig 3.5a). These results were 
highly consistent with the number of IL-17 A per 106 CD8+ T cells measured by 
intracellular cytokine staining (Fig 3 .Sb). 
3.4 Evaluation of IL-17 A expression kinetics at different time intervals following 
KdGag191-2os peptide stimulation: 
It has been previously shown in our laboratory that different cytokines are expressed at 
different time intervals following antigenic peptide stimulation [144]. Therefore, the 
expression kinetics of IL-17 A was evaluated at 6 hrs and 16 hrs following KdGag197-205 
peptide stimulation of splenocytes using intracellular cytokine staining. Results clearly 
indicated that there was no significant difference in the expression of IL-1 7 A at 6 hrs or 
16 hrs post peptide stimulation (Fig 3 .6). Also, both KO and BALB/c mice showed 
similar expression profiles. Interestingly, the IL-1 7 A expression kinetic pattern was 
similar to that observed for IFN-y (Stephanie Day Ph.D. thesis 2008). 
3.5 Evaluation of IFN-y and IL-17 A expression in lung: 
Previously, i.n/i.m immunizations have been shown to generate both mucosal and 
systemic immunity [132]. Also, studies have shown that following viral infections, 
CD4+ and CD8+ T cells express elevated IL-17 A in the lung [19]. Therefore, the 
expressions of IFN-y and IL-17 A by KdGag 197_205 specific CD8+ T cells in the lung were 
evaluated by intracellular cytokine staining. Results indicated that there was no 
significant difference in the IFN-y expression levels between IL-13-/- and wild type (Fig 
3.7). Even though, much greater IFN-y expression was observed in IL-4-/- and STAT6 -
/- compared to wild type BALB/c control mice. When the IL-17 A expression was 
examined unlike BALB/c mice, elevated IL-17 A expression was detected by KdGag197_ 
205 specific CD8+ T cells in the lung samples of IL-4-/- IL-13-/-, and STAT6-/- mice 
(Fig 3.8). 
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Recent studies have shown that, CD8+ T cells expressing IFN-y and IL-17 A are 
implicated in protective immunity [171]. Therefore, the HIV-specific CD8+T cells that 
express both IL-17 A and IFN-y were evaluated in the lung following i.n FPV-HIV /i.m 
VV-HIV prime-boost immunization. Data indicated that similar to the spleen responses, 
the expressions of IL..; 17 A and IFN-y double positive CD8+ T cells were elevated in IL-
13-/-, IL-4-/- and STAT6-/- mice compared to the wild type control mice (Fig 3.9). 
To further confirm the ICS data, IL-17 A ELispot was also performed. Unlike the 
spleen, due to a small sample size CD8+ T cells were not enriched for the lung. In 
BALB/c and KO mice, an enhanced number of IL-17 SFU were observed in both 
stimulated and unstimulated samples (Fig 3.10a, 3.10b). However, IL-4-/- mice 
exhibited greater numbers of IL-17 A SFU following KdGag197-205 stimulation compared 
to other KO mice. Interestingly, the ELispot data did not correlate with ICS data. These 
differences could be due to non-enriched lung cells used in these assays. 
3.6 Evaluation of transcription factor . ROR-yt protein . following prime-boost 
immunization: 
It is now established that the transcription factor, ROR-yt plays an important role in 
··-
regulating IL-17A expression in Thl 7 cells [57, 172]. In this study, the expression of 
ROR-yt from BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (by HIV-specific CD8+T cells) 
were evaluated at 6 hrs following peptide stimulation. Interestingly, no significant 
difference in ROR~yt protein expression was observed between stimulated and 
unstimulated CD8+ T cells obtained from BALB/c and KO mice (Fig 3 .11 ). However, 
IL-4-/- and STAT6-/- mice showed much greater background ROR-yt expression 
compared to BALB/c and IL-13-/-mice. The ROR-yt protein profile were IL-4-/- > 
0 • 
STAT6-/- > IL-13-/- _..: BALB/c suggesting IL-4 and STAT6 play role in modulating 
ROR-yt expression in BALB/c mice. 
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Fig 3.5: Evaluation of IL-17 A expression by HIV-specific CD8+ T cells 
using ELispot 
a) BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) mzce were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 14 
days post-booster immunization, splenocytes were prepared as described in 
materials and methods. CD8+ T cells from pooled spleen cells were 
negatively enriched and 4 x 106 cells were stimulated with I<1Gag197_2o5 
peptide for 2 4 hrs and IL-1 7 A expression was measured by ELispot. The 
graphs indicate the total number IL-1 7 A SFU per 106 CD8+ T cells 
compared to the number of IL-1 7 A cells per 106 CD8+ T cells measured by 
JCS. b) The error bars represent standard error of the mean (SEM). p 
values were calculated using student's two tailed unpaired t test *p=O. 030 
(BALB/c vs. IL-13-/-), **p=0.001 (BALB/c Vs. IL-4-1-) and ***p=0.004 
(BALB/c Vs. STAT6-/-). 
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Fig 3.6: Evaluation of IL-17 A expression kinetics following in/i.m FPV-
HIV NV-HIV prime-boost immunization 
BALBI c, IL-13-/-, IL-4-/- and ST AT6-/- (H-2d Background) mzce were 
prime-boost immunized with FPV-HIVIVV-HIV At 14 days post booster 
immunization, splenocytes were prepared and 4 x 106 cells were stimulated 
with .K'Gag191-2ospeptide for 6 hrs and 16 hrs in the presence of brefeldin-A 
and the expression of IL-1 7 A by CD8+ T cells were evaluated by 
intracellular cytokine staining. In all graphs, unstimulated cells were used 
as a background controls and were subtracted before plotting the data. The 
graph indicates the percentage of CD8+ T cells expressing IL-1 7 A at 
different time intervals. 
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Fig 3.7: Evaluation of lung specific IFN-y expression by HIV-specific 
CD8+ T cells following i.n/i.m FPV-HIVNV-HIV prime-boost 
immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) mice (n =4) were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 14 
days post booster immunization, lung cells were prepared as described in 
materials and methods. 4 x 106 cells were stimulated with K!Gag191-2os 
peptide for 16-20 hrs in the presence of brefeldin-A and IFN-y expression 
was evaluated by intracellular cytokine staining. a) The FA CS plots indicate 
pooled samples from each group. In all FA CS plots, the upper right 
quadrant (R3) indicates gates RI+ R2 and the numbers in the quadrant 
indicate the percentage of CD8+ IFN-y. b) The graph indicates the 
percentage of CD8+ T cells expressing IFN-y from each group as a pooled 
value fron1 n=4 mice/group. In all graphs, unstimulated cells were used as a 
background controls and were subtracted from each sample before plotting 
the data. Data are representative of tvvo independent experiments. 
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Fig 3.8: Evaluation of lung IL-17 A expression by HIV-specific CD8+ T 
cells following i.n/i.m FPV-HIV/VV-HIV prime-boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice (n =4) were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 14 
days post booster immunization, lung cells were prepared as described in 
materials and methods. 4 x 106 cells were stimulated with K1Gag191-2os 
peptide for 16-20 hrs in the presence of brefeldin-A and IL-1 7 A expression 
was evaluated by intracellular cytokine staining. a) The FACS plots indicate 
pooled samples from each group. In all FA CS plots, the upper right 
quadrant (R3) indicates RI + R2 and the numbers indicate IL-1 7 A producing 
CD8+ T cells as a percentage (top) and also the gated number of events 
(bottom) within brackets. b) The graph indicates the percentage of HIV-
specific CD8+ T cells expressing IL-1 7 A from each group as a pooled value 
from n=4 mice/group. In all graphs, unstimulated cells were used as a 
background controls and were subtracted from each sample before plotting 
the data. Data are representative of two independent experiments. 
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Fig 3.9: Evaluation of lung specific IL-17 A +IFN-y + ( double positive) 
HIV-specific CD8+ T cells following i.n/i.m FPV-HIVNV-IDV prime-
boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) mice (n=5) were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 14 
days post booster immunization, lung cells were prepared as described in 
materials and methods. 4 x 106 cells were stimulated with I<1Gag191-2o5 
peptide for 16-20 hrs in the presence of brefeldin-A and IL-17 A and IFN-y 
expression by CD8+ T cells was evaluated by intracellular cytokine staining. 
Unstimulated cells from each sample were used as background control. a) 
The FACS plots indicate pooled samples from each group. In all FACS 
plots, the upper right quadrant (R3) indicates gates RI + R2 and the numbers 
in the upper right quadrant indicate the percentage of CD8+ T cells 
producing IL-1 7 A and IFN-y. Also, the numbers in the upper left quadrant 
indicate the percentage of CD8+ IL-17 A+ and the numbers in the lower right 
quadrant represents the percentage of CD8+ IFN-y+. b) The graph indicates 
the percentage of CD8+ T cells expressing both IL-1 7 A and IFN-y from each 
group as a pooled value from n=4 mice/group. In all graphs, unstimulated 
cells were used as a background controls and were subtracted from each 
sample before plotting the data. Data are representative of two experiments. 
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Fig 3.10: Determining IL-17 expressions in the lung using ELispot 
Mice (n =4) from BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) 
were prime-boost immunized with FPV-HIVIVV-HIV At 14 days post 
booster immunization, lung samples were prepared and IL-1 7 A expression 
was measured by a) EL/spot, c) Intracellular cytokine staining as described 
previously. Unstimulated cells from each sample were used as background 
control. a) The graph indicates the total number IL-1 7 A SFU compared to 
the number of IL-1 7 A cells per 106 CD8+ T cells measured by JCS. b) 
Photograph of lung EL/spot plate. Data are representative of two 
experiments. 
0 
(a) EL/spot 
& 1000 Iii unstimulated 
A 
Iii stimulated u 800 
\C 
0 
1"""I 
1,.c 600 ~ 
Q. 
~ 400 ~ 
rJl. 
< 200 l-
1"""I 
I 
~ 0 ~ 
BALB/c IL-13 -/- IL-4 -/- STAT6 -/-
(b) 
Unstimulated Kct gag 191-2os Con-A 
I 
BALB/c 
IL-13-/-
IL-4-/-
'.41,::·.·····.f 
.F;'···· -: 
' .:; 
STAT6 -/-
(c)) JCS as 106 CDS T cells 
1200 il BALB/c 
+ 
lil IL-13 -/-00 A 1000 . u 
IG;I IL-4 -/-0 \C 
0 800 1"""I 
Iii STAT6 -/-1,.c 
~ 
Q. 600 < l-
1"""I 
I 400 ~ 
~ 
200 
0 
Fig 3.11: Evaluation of ROR-yt expression following i.n/i.m FPV-
HIVNV-HIV prime-boost immunization 
Mice (n=6) from BALB/c, IL-13-/ -, IL-4-/- and STAT6-I- (H-2d Background) 
were prime-boost immunized with FPV-HIVIVV-HIV At 14 days post 
booster immunization, 4 x 106 cells were stimulated with K1Gag197-205 
peptide for 6 hrs and the expression of ROR-yt by CD8+T cells were 
evaluated by intracellular cytokine staining. Unstimulated cells from each 
sample were used as background control. a) The FA CS plots indicate 
representative animals from each group. In all FA CS plots, the upper right 
quadrant (R3) indicate gates RI+ R2 and the numbers indicate the 
percentage of CD8+ T cells producing ROR-yt (top) and also the gated 
number of events (bottom) within brackets. b) Graph indicates the 
percentage of CD8+ T cells expressing ROR-yt from n=6 mice /group. The 
error bars represent standard error of the mean (SEM). p values were 
calculated using student 's t test *p=O. 02, (BALB/c Vs. IL-4-/-
Unstimulated) , **p= 0. OJ (BALB/c Vs. IL-4-/- stimulated). 
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3. 7 Discussion 
In the current study, both IL-1 7 A ELI spot and I CS data, clearly indicated that the 
expression of IL-17 A by HIV specific CD8+ T cells is significantly enhanced in IL-13-/-
, IL-4-/- and STAT6-/- mice compared to wild type BALB/c suggesting that these 
cytokines were involved in modulating IL-1 7 A. Out of the three KO mice groups tested, 
IL-4-/- mice showed the highest IL-17 A expression in both the spleen and the lung. It is 
well established that IL-4 and IL-13 are closely related and are regulated in a ST AT6 
dependent manner [152, 173]. Current observations were also consistent with some of 
the recent findings where the absence of IL-4 and IL-13 during epicutaneous 
sensitization was shown to enhance IL-17 production in IL-4 and IL-13 KO mice in 
both systemic compartment and lung. Also, among IL-4-/-, IL-13-/- and IL-4/IL-13 
DKO mice, IL-4 was identified as the key cytokine in down-regulating IL-17 expression 
in an asthma model [69]. Conney et al. have shown that IL-4 through STAT6 regulate 
STAT3 inhibition ofIL-17 at the IL-17A promoter [174]. Since IL-13 and IL-4 share a 
common STAT6 cell signaling regulatory pathway via IL-4Ra and IL-13Ral, there is a 
great possibility that both these cytokines regulate the expression of IL-17 A. The results 
obtained with STAT6-/- mice further substantiate this hypothesis. 
Studies by Cruz et al. have shown that following Mycobacterium bovis bacille Calmette 
Guerin infection, IFN-y deficient mice produced elevated number of IL-17-producing T 
cells [68]. Also, addition of exogenous IFN-y increased IL-12 and decreased IL-23 
mediated CD4 +IL-1 7 A expression suggesting that IFN-y down regulate IL-1 7 A 
expression. However, current data clearly demonstrate that in our HIV prime-boost 
model, high IFN-y expression does not correlate with the regulation of IL-17 A 
expression in CD8+ T cells. Furthermore, the majority of HIV-specific IL-17 A 
expressing CTLs also expressed IFN-y in both the spleen and lung. Also, the highest 
CD8+IL-17 A +IFN-y + was observed in IL-4 KO mice. Consistent with our findings, 
Weaver et al. have shown the emergence of IFN-y producing CD4 cells from Thl 7 
precursors in an IL-12-driven manner [175]. Studies have shown that these IL-17-
secreting cells can convert into IFN-y secreting cells suggesting that the cell phenotypes 
that express IL-17 A may be functionally plastic [176]. Moreover these studies 
indicated that the transcription factor ST A T3 could be involved in the polarization of 
IL-17 expressing cells and play a functional role in generating the IL-17 A +iFN-y +CD8 
T cells [176]. 
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Various studies have indicated that ROR-yt is one of the transcription factors involved 
in the regulation of IL-17 A producing cells [59, 65, 172, 177]. As transcription factors 
normally get activated several times prior to the protein expression, the expressions of 
ROR-yt in HIV-specific CD8+ T cells were analyzed at 6 hrs following HIV-specific 
peptide stimulation. Although, results showed no significant difference in the ROR-yt 
protein expression in HIV-specific CD8+ T cells between unstimulated and stimulated 
cells, there was an overall increased production of ROR-yt in IL-4-/- and STAT6-/-
mice compared to wild type control mice. The ICS data have shown that IL-4-/- and 
STAT6-/- mice produced higher IL-17 A upon KctGag197-205 peptide stimulation. This 
clearly suggests that ROR-yt plays an important role in regulating IL-17 A expression by 
HIV specific CD8+ T cells in IL-4-/- and STAT6-/- mice. Newcomb et al. have 
demonstrated that Th2 cytokines down regulate the ROR-yt expression either at mRNA 
level or under Thl 7 polarizing conditions [71]. Although IL-13-/- mice produced 
elevated IL-17 A expression, ROR-yt expressions were similar to BALB/c mice 
suggesting that in IL-13-/- mice, IL-17A expression may be regulated in a different 
manner or a time frame compared to IL-4 KO mice. Therefore, the expressions of other 
IL-17 A regulating factors at the mRNA level were also evaluated in IL-4 and IL-13 KO 
mice, which form the basis of the project (chapter 4). 
Upon MHC-I peptide stimulation, different cytokines are expressed at different time 
intervals and are regulated in a different manner in HIV -specific CD8+ T cells. For 
example, Ranasinghe et al. have shown that IL-2 and TNF-a were expressed by HIV -
specific CD8+ T cells at 3-4 hrs following KctGag 197_205 peptide stimulation whereas 
IFN-y expression can peak from 6-16 hrs [144]. Similarly, when the expression kinetics 
of IL-17 A was evaluated at both 6 hrs and 16 hrs of KctGag197_205 peptide stimulation no 
significant difference in the protein expression was observed suggesting that the 
expressi?n of IL-1 7A is more similar to the kinetics of IFN-y. 
C 
In conclusion, the data in this chapter clearly indicate that IL-4 and IL-13 can modulate 
IL-17 A expression by HIV-specific CD8+ T cells in systemic ( spleen) and mucosal 
(lung) compartments. In contrast, IFN-y is not involved in the regulation of IL-17 A in 
HIV specific CD8+ T cells, as most of the IL-17 A producing CD8+ T ·cells were also 
positive for IFN-y. Previously, Ranasinghe et al. have shown that IL-4, IL-13 and 
STAT6 are involved in regulating the avidity of HIV-specific CD8+ T cells [165] and 
-
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protective immunity Ranasinghe et al. (Submitted June 2012). In this study, IL-4, IL-13 
and ST AT6 have also been shown to modulate IL-17 A expression by HIV-specific 
CD8+ T cells ; data suggest that IL-17 A could play a direct or indirect role in modulating 
HIV-specific CD8+ T cell avidity. 
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CHAPTER 4: Regulation of IL-17 A in HIV-specific CD8+T 
cells following HIV-1 prime-boost immunization 
36 
4.1 Introduction 
The differentiation of T cell subsets into Thl or Th2 or Thl 7 cells is regulated by the 
lineage specific cytokines which signals through their ST AT proteins to activate their 
corresponding transcription factors [178]. These transcription factors can concurrently 
promote their own lineage differentiation and inhibit its alternative-differentiating 
pathway (Gene repression) [179]. For example, the expression of i) T-bet differentiates 
Thl pathway, ii) GATA3 mediate Th2 pathway, iii) ROR-yt in Thl 7 pathway and iv) 
Foxp3 in Treg differentiation (Fig 4.1). 
Thl 7 cells have emerged as an independent subset of T cells and exhibit distinct 
cytokine and transcriptional profile [50]. The differentiation of Thl 7 cells begins with 
the combined initiation of IL-6 and TGF-~ to activate the Janus-kinase pathway thereby 
initiating STAT3 signaling of ROR-yt transcription [180]. Following differentiation, IL-
21 is required for the amplification of Thl 7 response and IL-23 is involved in the 
maintenance of Thl 7 expression (Fig 4.2). 
Results from previous chapter (3) have shown that IL-4, IL-13 and STAT6 regulate the 
expression of IL-17 A following HIV prime-boost immunization. Therefore, in this 
study, the expression IL-17 A regulatory functions in CD8+ T cells were evaluated 
following HIV-specific (KctGag197_205 ) peptide stimulation in BALB/c, IL-4-/-, IL-13-/-
and STAT6-/- mice at the mRNA level. Specifically, the expression of cytokines (IFN-
y, IL-6, IL-l 7A, IL-23a), and transcriptional factors (T-Bet, TGF-~, GATA3, and ROR-
yt) in KdGag1 91-2os specific CD8+ T cells were measured. In addition, relative expressions 
of T-bet and GAT A3 were also evaluated to elucidate whether these played any role in 
IL-17 A regulation. Finally, the expression of above gene functions were also examined 
in KdGag 191-2os tetramer reactive CD8+ T cells, (where the cells were not stimulated) at 
500-sorted cells per group. 
4.2 Understanding the transcriptional regulation profile of IL-17 A in BALB/c and 
GKO mice: 
The transcriptional regulation of IL-17 A following i.n/i.m. FPV-HIV NV-HIV prime-
boost immunization was characterized using IL-13-/- IL-4-/-, STAT6-/- and BALB/c 
control mice. CD8+ T cells were negatively isolated and were stimulated with KdGag197-
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205 peptide for 16 hrs. RNA was extracted, cDNA was synthesized and RT-PCR was 
performed. 
Firstly, the mRNA expressions of TGF-{3, IL-6 were analyzed and data indicated that 
the relative expressions of these factors were highly elevated in IL-4-/- mice (Fig 4.3). 
The expression levels were not significantly different in BALB/c, IL-13-/- and STAT6-
/- mice. When the ROR-yt mRNA level was examined, elevated mRNA copy numbers 
were observed in IL-4-/-, IL-13-/- and STAT6-/- mice compared to BALB/c mice. 
However, no elevated expression of IL-23a mRNA by HIV-specific CD8+ T cells were 
observed in all the mice tested. Finally, when the IL-17 A mRNA levels were compared 
against the transcriptional factors, IL-17 A mRNA profile correlated with TGF-~ and . 
ROR-yt expressions eliciting higher levels in IL-4-/-, IL-13-/-, STAT6-/- compared to 
BALB/c control mice (Fig 4.3). In summary, current data suggests that the 
transcriptional regulation of IL-17 A in HIV-specific CD8+ T cells was dependent on IL-
4, IL-13 and STAT6. More strikingly, TGF-{3, IL-6, ROR-yt and IL-17A mRNA played 
a significant role in IL-4-/- mice compared to IL-13-/- or STAT6-/- mice (Table 4.1). 
As at 16 hrs post HIV-specific peptide stimulation, IL-6 and IL-23a mRNA levels were 
found to be low in these HIV-specific CD8+ T cells. Therefore_, the expression kinetics 
of these IL-1 7 A regulatory factors were also examined at 4 hrs and compared with 16 
hrs. Interestingly, data indicated no significant elevated expression of IL-17 A, TGF-~, 
IL-6, ROR-yt or IL-23a was observed at 4 hrs of peptide stimulation compared to 16 hrs 
(Fig 4.4). 
4.3 Role ofT-bet and GATA3 expression in IL-17A regulation: 
Transcription factors T-bet (regulating IFN-y) and GATA3 (down stream regulator of 
IL-4/IL-}3) mRNA expressions levels were also assessed to confirm whether the 
expression of these transcription factors played any role in IL-1 7 A regulation ip HIV -
specific ·cog+ T cells (Fig 4.5). Although the IL-17 A mRNA expression profile was IL-
4-/- > IL-13-/- > STAT6-/- > BALB/c, this pattern did not correlate with T-bet and 
GATA3 mRNA expressions profiles (Fig 4.6). For example, BALB/c mice that 
expressed T-bet and GATA3 mRNA did not produce IL-17A or ROR-yt (Fig 4.3). This 
clearly indicated that T-bet and GATA3 were not involved in the regulation of IL-17 A 
in HIV-specific CD8+ T cells. Interestingly, T-bet mRNA levels were also elevated in 
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Fig 4.1: Schematic diagram of differentiation of Thl, Th2, Thl 7 and 
Treg cells 
T cells are divided into at least four lineages, namely, Thi , Th2, Thi 7 and 
Treg. These cells express master regulatory transcription factors T-bet, 
GATA3, ROR-yt and Foxp3 that regulate IFN-y, IL-4, IL-1 7 and TGF-/3, Il-
l O expression respectively. 
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Fig 4.2: Regulation of IL-17 A expression by Thl 7 cells 
It is established that TGF-/3 together with IL-6 enhances expresszon of 
ROR-yt and promotes development of Thl 7 cells secreting IL-1 7A. Once 
differentiated, IL-23 stabilizes the IL-1 7 A expression through ROR-yt 
signaling (180). 
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Fig 4.3: Transcriptional regulation profile of IL-17 A in BALB/c and 
KO mice in HIV-specific CD8+ T cells following i.n/i.m prime-boost 
immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice (n =4) were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 2 
weeks post booster immunization, CD8+T cells from splenocytes were 
negatively enriched and stimulated with K!'Gag191-205 peptide for 16 hrs. 
RNA was isolated, cDNA was synthesized and real-time PCR was 
performed in duplicates to assess the changes in the mRNA levels. Data 
show the relative mRNA copy numbers of TGF-/3, IL-6, ROR-yt, IL-23a and 
IL-l 7A of stimulated cells after normalizing against L32 expression. These 
exp eriments were repeated twice and similar trends were observed. 
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Table 4.1: Summary of IL-17 A regulation following prime-boost 
immunization 
Data indicate that the mRNA copy numbers of IL-6, IL-1 7 A, IL-23a, TGF-/3 
and ROR-yt were elevated in IL-4-/- mice compared to the other groups 
tested. 
*Note: No expression of IL-23a was detected. 
IL-6 TGF-p ROR-yt IL-23 * IL-17 
STAT6-/- ± . ++ .• +± + 
BALB/c + ± ± 
Fig 4.4: Expression kinetics of IL-17 A regulating factors in IDV-
specific CD8+ T cells following prime-boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice (n=4) were 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 2 
weeks post-booster immunization, CD8+T cells from splenocytes were 
negatively enriched and stimulated with I<1Gag191-2os peptide for 4 hrs and 
16 hrs. RNA was isolated at different time points, cDNA was synthesized 
and real-time PCR was performed in duplicates to assess the changes in the 
mRNA levels at these different time-points. Data show TGF-/3, IL-6, ROR-yt, 
IL-23a and IL-1 7 A mRNA copy numbers at 4 hrs and 16 hrs of I<1Gag191-2os 
peptide stimulation normalized against the house-keeping L32 mRNA 
expression. These experiments were repeated twice and similar trends were 
observed. 
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Fig 4.5: Schematic diagram indicating the regulation of IL-17 A in HIV-
specific CD8+ T cells 
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Fig 4.6: Evaluation of IL-17 A, T-bet and G AT A3 in HIV-specific CD8+ 
T cells following prime-boost immunization in BALB/c and KO mice 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice (n=4) were 
prime-boost immunized with FPV-HJV/ VV-HIV (control vaccine). At 2 
weeks post booster immunization, CD8+T cells from splenocytes were 
negatively enriched and stimulated with K!1Gag197-205 peptide for 16 hrs. 
RNA was isolated, cDNA was synthesized and real-time PCR was 
performed to assess the changes in the mRNA profiles of the transcription 
factors T-bet and GATA3 compared to IL-1 7A. Graph show that the mRNA 
expression of IL-l 7A, T-bet, GATA3 normalized against L32 expression. 
These experiments were repeated twice and similar trends were observed. 
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IL-4-/- mice compared to other KO mice, which correlated with the IFN-y production 
by these mice (Fig 4. 7). 
4.4 Evaluation of IFN-y and IL-17 A mRNA expression following KdGag191-2os 
peptide stimulation: 
As some reports have suggested that IFN-y negatively regulate IL-17 A expression, in 
this study the expression of IFN-y and IL-17 A mRN As were again assessed to see 
whether IFN-y influenced IL-17 A expression at the transcriptional level. As the 
expression of both IFN-y and IL-l 7A mRNA (Fig 4.7), and protein (Fig 3.2) profile 
were very similar in HIV-specific CD8+T cells eliciting (IL-4-/- > IL-13-/- > STAT6-/-
> BALB/c) (Fig 4.7), data clearly indicated that IFN-y did not modulate the expression 
of IL-17 A even at the transcription level or translational level. The T-bet expression 
pattern further substantiated these observations ( 4.6). 
4.5 Evaluation of granzyme-B and IL-17 A mRNA expression in HIV-specific COS+ 
T cells following prime-boost immunization: 
Studies have shown that CD8+ T cells producing IL-17 can be less cytotoxic [181 ], 
therefore, the expressions of IL-17 A and granzyme-B were also assessed following 
KdGag197-205 peptide stimulation as discussed in materials and methods. Results showed 
that the relative mRNA expression of IL-17 A and granzyme-B were higher in KO mice 
compared to wild type BALB/c mice (Fig 4.8). The mRNA expression profile of 
granzyme-B was IL-13-/- > STAT6-/- > IL-4-/- > BALB/c. Interestingly, the IL-4-/- and 
IL-13-/- granzyme-B expression inversely correlated with the IL-17 A expression in 
these mice. This data is consistent with previous findings in our laboratory where 
elevated granzyme-B by IL-13-/- HIV-specific CD8+ T cells were observed compared to 
BALB/c mice [165]. 
4.6 Evaluation of cytokines and transcription factors in HIV-tetramer reactive 
COS+ T cells: 
The transcription factors that were involved in IL-17 A regulation were also analyzed in 
HIV-specific tetramer reactive CD8+ T cells. Following prime-boost immunization 
tetramer specific CD8+ T (500 cells/well) were FACS sorted into 96 well plates cDNA 
was synthesized (without any KdGag 197_205 peptide stimulation) and RT-PCR was 
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performed. No IL-6, IL-17A, TGF-~ and ROR-yt mRNA was detected in these tetramer 
specific CD8+ T cells unlike IFN-y and granzyme-B expression as observed in previous 
studies [ 144]. This indicated that IL-1 7 A was not induced when cells were not 
stimulated with HIV -specific peptide. 
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Fig 4.7: Evaluation of IL-17A and IFN-y mRNA expression in HIV-
specific CD8+ T cells from BALB/c, IL-4-/-, IL-13-/-, and STAT6-/- mice 
following prime-boost immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-/- (H-2d Background) mice (n=4) vvere 
prime-boost immunized with FPV-HIVIVV-HIV (control vaccine). At 2 
weeks post-booster immunization, CD8+ T cells from splenocytes were 
negatively enriched and stimulated with K1Gag191-2os peptide for 16 hrs. 
RNA was isolated, cDNA was synthesized and real-time PCR was 
performed to evaluate the fold change in the mRNA levels compared to 
unstimulated background control. Data show the mRNA fold change of IFN-
y and IL-1 7A compared to the unstimulated control normalized against L32 
expression as described in materials and methods. These experiments were 
repeated twice and similar trends were observed. 
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Fig 4.8: Evaluation of IL-17 A and granzyme-B mRNA expression in 
BALB/c, IL-4-/-, IL-13-/-, and STAT6-/- mice following prime-boost 
immunization 
BALB/c, IL-13-/-, IL-4-/- and STAT6-I- (H-2d Background) mice (n =4) were 
prime-boost immunized with FPV-HIV/ VV-HIV (control vaccine). At 2 
weeks post-booster immunization, CD8+T cells were negatively enriched 
and stimulated with K1Gag191-2os peptide for 16 hrs. RNA was isolated, 
cDNA was synthesized and real-time PCR was performed to evaluate the 
fold change in the mRNA levels compared to unstimulated background 
control. Data show the mRNA fold change of IL-1 7A and granzyme-B 
compared to the unstimulated control normalized against L3 2 expression. 
These experiments were repeated twice and similar trends were observed. 
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4. 7 Discussion 
Previous studies have shown that IL-6 and TGF-~ directs the induction of IL-l 7A 
expression in CD4+Thl 7 cells [182, 183]. Current data clearly demonstrated that there 
is an elevated IL-6 and TGF-~ mRNA expression in IL-4-/-, IL-13-/- and STAT6-/-
mice compared to BALB/c. However, IL-4-/- mice showed the highest TGF-~ and IL-6 
mRN A expressions compared to other groups tested. Hence, data indicate that the 
induction of IL-17 A expression in HIV -specific CD8+ T cells is strongly regulated by 
TGF-~ and IL-6 in an IL-4 dependent manner (Table 4.1). 
Studies by Huber et al. have shown that, TGF-~ can enhance Thl 7 programming by 
inducing ROR-yt, ROR-a, IL-23R expression in CD8+ T cells in the presence of IL-6 
and IL-21 [181 , 184]. Current data showed that ROR-yt mRNA copy numbers were 
higher in IL-4-/-, IL-13-/- and STAT6-/- mice compared to BALB/c control. Although, 
ROR-yt is the master transcriptional factor involved in the regulation of IL-17 A [177] , 
current data clearly indicate that ROR-yt plays a minor role in regulating IL-17 A 
expression in HIV -specific CD8+ T cells compared to TGF-~. 
Interestingly, the mRNA copy numbers of TGF-~, IL-6, ROR-yt, IL-17A mRNA were 
increased at 16 hrs of KdGag197_205 peptide stimulation compared to 4 hrs in all the KO 
groups tested. This could possibly be due to the increased rate of transcription at 16 hrs. 
Previously in chapter 3 at the protein level, the expression of ROR-yt was increased at 6 
hrs of KdGag1 97_205 peptide stimulation. The mRNA data showed that there was less 
ROR-yt mRNA expressions at 4 hrs compared to 16 hrs. This suggests that most likely 
the ROR-yt transcription occurs between 4 hrs and 6 hrs of peptide stimulation. Thus, 
evaluating the mRNA expression kinetics at several time points (i.e. 5, 6, 7, 8 hrs) may 
provide better understanding of the IL-17 A kinetic profile in HIV-specific CD8+ T cells. 
Although IL-23 has been demonstrated in the proliferation and persistence of IL-17 A 
production in CD4+Thl 7 cells following HIV-1 prime-boost immunization current 
data showed no observable increase in the expression of IL-23a in HIV-specific CD8+ T 
cells in any of the groups tested. Data suggest that unlike CD4+ T cells [20 21 67] IL-
23 is not required for the induction of IL-17 A in HIV-specific CD8+ T cells. 
The relative expression of IL-17A mRNA copy numbers were higher in IL-4-/- IL-13-/-
and STA T6-/- mice compared to BALB/c control mice. These results were highly 
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consistent with the findings by He et al. where IL-4-/-, IL-13-/- and IL-4/IL-13-/- mice 
showed elevated IL-17 A mRNA expression level by Thl 7 cells upon OVA sensitization 
[69]. The current IL-17 A mRNA expression profile in KO mice was similar to the 
protein expression data showing IL-4-/- > IL-13-/- > STAT6-/- > BALB/c mice (table 
4.1 ). This further confirmed that IL-17 A expression by HIV-specific CD8+ T cells could 
mainly be IL-4 dependent and not IL-13. 
Previous studies have shown that, both T-bet and eomesodermin (Eomes) (Thl 
transcription factor) can regulate the expression of ROR-yt and IL-17 A expression 
[185]. Current data clearly indicated that both T-bet and GATA3 did not significantly 
influence the transcriptional regulation of IL-17 A expression in HIV-specific CD8+ T 
cells, suggesting that IFN-y (regulated by T-bet) may not play a role in dampening IL-
17 A expression. For example both ROR-yt and T-bet were highest in IL-4-/- mice. 
Chapter-3 results have also shown that IL-4-/- mice produced highest CD8+IL-17+IFN-
y +cells.Interestingly, the level of GATA3 mRNA expressions was higher in all the KO 
groups tested. It is well established that GATA3 play a important role in IL-4/IL-13 
regulation [186] [187]. Studies by Ouyang et al. have shown that GATA3 activation of 
T cells can occur independent of STAT6 signaling [188] and also, it has been well 
studied that the IL-4 and IL-13 can compensate each other in the absence of one to 
initiate the Th2 mediated immune response [189-191]. 
Previously, Tajima et al. have shown that nai"ve CD8+ T cells from OT-1 TCR 
transgenic mice produced higher IFN-y and granzyme-B mRNA expression under Thl 
polarizing conditions and IL-17 A and ROR-yt under Thl 7 polarizing conditions 
suggesting that Thl cells were strongly cytotoxic whereas Thl 7 cells most likely not 
cytotoxic [171, 181]. Current data indicated that IFN-y and IL-17A were highest in IL-
4-/- mice (chapter 3). However, granzyme-B and IL-17A expressions showed an inverse 
relationship with IL-13 and IL-4 KO mice suggesting that HIV -specific CD8+ T cells 
obtained fro1n IL-13 KO mice could possibly be highly cytotoxic compared to CD8+ T 
obtained from IL-4 KO mice. In our laboratory, Quah et al. have designed a novel assay 
to look at the cytotoxicity and most likely; this assay could evaluate this function of IL-
13 and IL-4 KO mice, which warrants further investigation. 
In summary, current data indicate that the IL-17 A expression at the mRNA level was 
regulated,,mainly by TGF-~ and IL-6, and to a lesser extent ROR-yt but not IL-23a. 
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Following HIV-specific peptide stimulation, T-bet and GA T A3 did not play any role in 
regulating IL-17 A expression in HIV-specific CD8+ T cells. Data indicated that in wild 
type BALB/c mice, IL-4, IL-13 and STAT6 down regulate the IL-17 A mRNA 
expression by HIV-specific CD8+ T cells. In contrast, IFN-y did not dampen the IL-17 A 
mRNA expression by HIV-specific CD8+ T cells. Granzyme-B and IL-17 A expressions 
were inversely correlated in IL-13 and IL-4 KO mice suggesting that in IL-13-/- mice, 
HIV-specific CD8+ T cells could be more cytotoxic than IL-4 -/- mice which needs to be 
confirmed using the cytotoxicity assay. 
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CHAPTER 5: Evaluate the IL-17 A expression by HIV-
specific CD8+ T cells in response to the novel IL-13 inhibitor 
• vaccine 
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5.1 Introduction: 
Studies in our laboratory have shown that i.nJi.m prime-boost immunization can induce 
high magnitude (measured by IFN-y) and high avidity HIV specific effector and 
memory CD8+ T cell responses in BALB/c mice [144]. Studies using IL-13-/-, IL-4-/-
mice, have further substantiated that IL-13 and IL-4 are involved in regulating the 
avidity of HIV-specific CTLs [ 165]. Recently, Ranasinghe et al. have developed an 
HIV pox-viral based vaccine that co-expresses HIV gag/pol and IL-13 soluble receptor 
(IL-13Ra2), which can temporarily inhibit the expression of IL-13 in vivo. This IL-13 
inhibitor vaccine strategy (FPV-HIV IL-13Ra2NV-HIV IL-13Ra2) has shown to 
enhance both the magnitude and avidity of HIV-specific CD8+ T cells compared to the 
control vaccine (FPV-HIVNV-HIV) (Ranasinghe et al. submitted May 2012). Various 
studies have shown that IL-17 A is involved in protective immunity [27, 192]. As 
chapters 3 and 4 have clearly shown that IL-4 and IL-13 can modulate IL-17 A 
expression, in this study, the expression of IL-17 A was evaluated at acute, effector, 
memory stages and following influenza-HIV challenge using the novel IL-13 inhibitor 
vaccine to further establish whether IL-17 A expression was a hallmark of protective 
immunity and some how involved in modulating T cell avidity. 
5.2 Evaluation of IFN-y and IL-17 A expression by HIV-specific effector CD8+ T 
cells following novel IL-13 inhibitor vaccine: 
To evaluate the expression of IFN-y and IL-17A following novel IL-13 inhibitor 
vaccine, firstly , mice (n=S-8) were prime-boost immunized with either FPV-HIVNV-
HIV (control vaccine) or FPV-HIV IL-13Ra2/VV-HIV IL-13Ra2 (IL-13 inhibitor 
vaccine) as described in methods. At 14 days post booster immunization, the expression 
of IFN-y and IL-17 A by CD8+ T cells were evaluated by intracellular cytokine staining 
and IL-1 7 A ELispot. 
Results indicated that the IL-13 inhibitor vaccine generated significantly higher 
expression of IFN-y compared to the control vaccine (Fig 5 .1 ), which was consistent 
with previous studies in our laboratory (Ranasinghe et al. submitted in May 2012). 
When IL-1 7 A expression was evaluated, data clearly indicated that, at 14 days post 
booster immunization, IL-13 inhibitor vaccine could induce elevated KdGag191-2os 
specific CD8+ T cells that expressed IL-1 7 A. Interestingly, control vaccine showed no 
detectable IL-17 A expression by HIV -specific CD8+ T cells (Fig 5 .2). In this study, the 
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responses observed by IL-13 inhibitor vaccine were much lower compared to the IL-13-
/- mice ( chapter 3) possibly due to the transient inhibition by the novel IL-13 inhibitor 
vaccine unlike the KO mice. 
To further confirm the IL-1 7 A expression, ELI spot was also performed by enriching the 
CD8+ T cells as described previously in chapter 2. The IL-13 inhibitor vaccine results 
were consistent with the IL-17 A intracellular cytokine staining data, where elevated 
number of IL-17 A SFU were observed in the spleen following KdGag197_205 peptide 
stimulation. However, unlike ICS, where total splenocytes were used control vaccine 
also showed around twenty IL-17A SFU produced by CD8+T cells (Fig5.3). 
5.3 Evaluation of lung specific IFN-y and IL-17 A expression by HIV-specific CD8+ 
T cells following novel IL-13 inhibitor vaccine: 
The above data (Fig 5.1 and 5.2) indicated that the expression of splenic CD8+ IFN-y 
and IL-1 7 A production was higher in the IL-13 inhibitor vaccine compared to the 
control vaccine. Therefore, the expressions of IFN-y and IL-17 A by CD8+ T cells in the 
lung (n=5-8) were also examined to assess whether the vaccines induced immunity in 
the mucosae. Results indicated that the IFN-y and IL-1 7 A production was enhanced in 
lung at 14 days post booster immunization similar to that of spleen compared to the 
control vaccine (Fig 5.4 and 5.5). 
Then the total number of IL-17 A SFU in the lung was further examined by ELispot, 
(note that the cells were not enriched due to small sample size) and results clearly 
sh?wed .that the total number IL-1 7 A expression by lung specific T cells following 
KdGag197_205 peptide stimulation were higher in IL-13 inhibitor vaccine compared to the 
control vaccine (Fig 5.6). However; data indicated that unlike the spleen where CD8+ T 
cells Wyre negatively isolated, there was spontaneous IL-17 A production by cells other 
than CD8+ T cells as elevated IL-17 SFU were observed in the unstimulated control. 
These background numbers were higher in the novel IL-13 inhibitor vaccine compared 
to the control vaccine. 
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Fig 5.1: Evaluation of IFN-y expression by systemic HIV-specific 
effector CD8+ T cells following novel IL-13 inhibitor vaccine 
BALB/c (H-2d Background) mice were prime-boost immunized with FPV-
HIVIVV-HIV (control vaccine) or FPV-HIV IL-13Ra2/ VV-HIV IL-13Ra2 
(IL-13 inhibitor vaccine). At 14 days post-booster immunization, 
splenocytes were prepared as described in materials and methods. 4 x 106 
cells were stimulated with K!1Gag197_2ospeptide for 16-20 hrs in the presence 
of brefeldin-A to evaluate IFN-y expression by intracellular cytokine 
staining. a) The FA CS plots indicate representative animals from each 
group. In all FACS plots, the upper right quadrant (R3) indicates gates 
RI + R2 (see fig 3.1) and the numbers indicate the percentage of CD8+ T 
cells producing IFN-y. b) The graph indicates the percentage of CD8+T 
cells expressing IFN-y (n =5-8 mice) where the stimulated samples were 
subtracted from the unstimulated background. Data are representative of 
three independent experiments and error bars represents standard error of 
the mean (SEM). p values were calculated using two tailed un-paired 
student 's t test *p=O.0001. 
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Fig 5.2: Evaluation of IL-17 A expression by systemic HIV-specific 
effector CDS+ T cells following novel IL-13 inhibitor vaccine 
BALB/c mice were prime -boost immunized with FPV-HIVIVV-HIV (control 
vaccine) or FPV-HIV IL-13Ra2/ VV-HIV IL-13Ra2 (IL-13 inhibitor 
vaccine). At 14 days post booster immunization, splenocytes were prepared 
as described in materials and methods. 4 x 106 cells were stimulated with 
K1Gag191-2ospeptide for 16-20 hrs in the presence of brefeldin-A to evaluate 
IL-1 7 A expression by intracellular cytokine staining. a) The FA CS plots 
indicate representative animals from each group. In all FACS plots the 
upper right quadrant (R3) indicates gates RI + R2 and the numbers indicate 
IL-1 7 A producing CD8+ T cells as a percentage (top) and the number of 
events (bottom within brackets). b) The graph indicates the percentage of 
CD8+ T cells expressing IL-17A (n=5-8 mice) in each group. In all graphs, 
unstimulated cells were used as a background controls and were subtracted 
from each sample before plotting the data. The data are representative of 
three independent experiments and error bars represents standard error of 
the mean (SEM). p values were calculated using two-tailed un-paired 
student 's t test *p=O. 025. 
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Fig 5.3: Evaluation of splenic IL-17 A expression following novel IL-13 
inhibitor vaccine using ELispot compared to ICS 
BALB/c (H-2d Background) mice were prime-boost immunized with FPV-
HIVIVV-HIV (control vaccine) or FPV-HIV IL-l 3Ra2/ VV-HIV IL-l 3Ra2 
(IL-13 inhibitor vaccine). Splenocytes were harvested and IL-17A 
expression was measured by a) IL-1 7 A EL!spot using negatively isolated 
CD8+T cells as described previously and b) intracellular cytokine staining. 
The graphs represent a) the total number IL-17 SFU per 106 CD8+ T cells 
measured by EL!spot, compared to the number of IL-1 7 cells per 106 CD8+ 
T cells measured by JCS. Unstimulated cells from each sample were used as 
background controls. The data represent mean plus standard error of the 
mean (SEM). p values were calculated using two-tailed un-paired student 's 
t test *p=O. 03 7. Data are representative of three independent experiments. 
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Fig 5.4: Evaluation of IFN-y expression by lung HIV-specific effector 
CD8+ T cells following novel IL-13 inhibitor vaccine 
BALB/c (H-2d Background) mice (n =5) were prime-boost immunized with 
FPV-HIV/ VV-HIV (control vaccine) or FPV-HIV IL-13Ra2/ VV-HIV IL-
13Ra2 (IL-13 inhibitor vaccine). At 14 days post booster immunization, 
lung cells were prepared as described in materials and methods and 4 x 106 
cells were stimulated with .K!Gag191-2ospeptide for 16-20 hrs in the presence 
of brefeldin-A and IFN-y expression was evaluated by intracellular cytokine 
staining. a) The FACS plots indicate data pooled.from animals (n =5 mice). 
In all FACS plots, the upper right quadrant (R3) indicates gates Rl + R2 and 
the numbers in the quadrant indicate the percentage of CD8+ T cells 
producing IFN-y. b) The graph shows the representative data from two 
experiments where the samples were pooled from each group. 
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Fig 5.5: Evaluation of IL-17 A expression by lung HIV-specific effector 
CD8+ T cells following novel IL-13 inhibitor vaccine 
BALB/c (H-2d Background) mice (n =5) were prime-boost immunized with 
FPV-HIVIVV-HIV (control vaccine) or FPV-HIV IL-l 3Ra2/ VV-HIV IL-
l 3Ra2 (IL-13 inhibitor vaccine). At 14 days post booster immunization, 
lung cells were prepared as described in materials and methods. 4 x 106 
cells were stimulated with KGag197-205peptide for 16-20 hrs in the presence 
of brefeldin-A and IL-1 7 A expression was evaluated by intracellular 
cytokine staining. a) The FA CS plots indicate pooled animals from each 
group. In all FACS plots, the upper right quadrant (R3) indicates gates 
RI + R2 and the numbers indicate IL-1 7 A producing CD8+ T cells as a 
percentage (top) and the number of events (bottom within brackets) . 
Unstimulated cells from each sample were used as background control. b) 
The graph indicates representative data from two independent experiments. 
In all graphs, unstimulated cells were used as a background controls and 
were subtracted from each sample before plotting the data. 
w· 
0 
-
M 
0 
-
N 
0 
.... 
0 
u 
~ 
< 1 
< 0 t-- -
~ M 
I 0 ~ 
-~ 
N 
0 
-0 
0 
0 
-
0.04 
0 
(a) 
Unstimulated 
0.02% 0 
(~ O) M 0 
N 
0 
-0 
0.01 o/o 0 
(8) M 0 
N 
0 
0 
0 
0 
100 101 102 103 -10 
CD8PE 
(b) 
Stimulated 
(11 ) 
. (28) 
.. . 
.. . 
100 101 102 103 104 
Control Vaccine 
IL-13 Inhibitor 
Vaccine 
D Control vaccine 
• IL-13 Inhibitor vaccine 
Fig 5.6: Evaluation of lung specific IL-17 A expression following IL-13 
Inhibitor vaccine using ELispot compared to ICS 
BALB/c (H-2d Background) mzce (n =5) per group were prime-boost 
immunized with FPV-HIVIVV-HIV (control vaccine) or FPV-HIV IL-
l 3Ra2/ VV-HIV IL-l 3Ra2 (IL-13 inhibitor vaccine) . At 14 days post booster 
immunization, lung samples were prepared and stimulated with K1Gag197-205 
peptide as described previously and IL-1 7 A expression was measured by a) 
IL-1 7 A ELI spot and b) intracellular cytokine staining. The graphs represent 
a) the total number IL-1 7 SFU per 106 CD8+ T cells measured by EL!spot 
compared to the number of IL-1 7 cells per 106 CD8+ T cells measured by 
JCS. Unstimulated cells from each sample were used as background 
controls. Data are representative of two experiments. 
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5.4 Comparison of IL-17 A expression by KdGag197-2os specific CD8+ T cells at 
acute, effector, memory and following influenza-HIV-challenge: 
As the IL-1 7 A expression was found to be elevated at 14 days in IL-13 inhibitor 
vaccine compared to the control vaccine, the expression of IL-17 A by KdGag197-2os 
specific CD8+ T cells at different time intervals following prime-boost immunization 
was evaluated. Results indicated that at 3 days post booster vaccination, both vaccines 
induced the lowest IL-17 A expression in HIV specific CD8+ T cells compared to 14 
days (Fig 5.7). However, at 8 weeks (memory phase), IL-17A expression by KdGag 197_ 
205 specific CD8+ T cell was significantly enhanced in IL-13 inhibitor vaccine compared 
to the control vaccine. To further evaluate the protective role of IL-17 A, mice were 
immunized with both the vaccines and challenged with a model influenza-HIV virus 
challenge. The data clearly indicated that there was elevated IL-17 A expression by 
KdGag1 97-2os specific CD8+ T cells following IL-13 inhibitor vaccine compared to the 
control vaccine or the unimmunized control mice that received the influenza-HIV 
challenge. Furthermore, these results were also consistent with ELispot data where 
higher number of IL-17 SFU were observed at effector stage and following influenza-
HIV challenge. In summary, the expression profile of IL-17 A following vaccination 
was found to be influenza-HIV challenge> effector> memory> acute phase (Fig 5.7). 
Similarly, when the IL-17 A expression was evaluated in the lung, no expression of IL-
17 A by KdGag197-2os specific CD8+ T cells were observed at 3 days or 8 weeks post 
booster immunization (Fig 5.8). In contrast, at 14 days and following influenza-HIV 
challenge, the expression of IL-l 7A was greatly enhanced (Fig 5.8) in IL-13 inhibitor 
vaccine compared to the control and unimmunized mice. Unlike the splenic HIV-
challenge ELispot data, lung data did not match what was observed with ICS as higher 
SFU were detected in the unstimulated lung samples of IL-13 inhibitor vaccine. 
However, lung ICS data indicated that IL-17 A expression by HIV-specific CD8+ T cells 
were specific to the novel vaccine. Following IL-13 inhibitor vaccine, the IL-17 A 
expression profile in the lung was found to be influenza-HIV challenge > effector > 
memory > acute. 
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Fig 5. 7: Comparative analysis of IL-17 A expression by systemic 
~Gag197-2os specific CD8+ T cells at acute, effector, memory and 
following influenza-HIV challenge 
BALB/c (H-2d Background) mice (n =5-8) were prime-boost immunized with 
FPV-HJV/VV-HIV (control vaccine) or FPV-HIV IL-13Ra2/ VV-HIV IL-
13Ra2 (IL-13 inhibitor vaccine). At 3 days, 14 days, 8 weeks and influenza-
HIV challenge, spleen samples were harvested and 4 x 106 cells were 
stimulated with 16-20 hrs of K:'Gag191-2ospeptide stimulation, the expression 
of IL-1 7 A by CD8+ T . cells were evaluated by IL-1 7 A ELispot and 
intracellular cytokine staining. The FACS plots indicate representative 
animals from each group. a) In all FA CS plots, the upper right quadrant 
(R3) indicates RI + R2 and the numbers indicate IL-1 7 A producing CD8+ T 
cells as a percentage (top) and also the gated number of events (bottom 
within brackets). b) Graph represents the percentage of CD8+ T cells 
expressing IL-1 7 A where the unstimulated background value was 
subtracted. The data represents mean of three independent experiments and 
error bars indicate standard error of the mean (SEM). p values were 
calculated using student 's two tailed unpaired t test, (*p =O. 025) and 
**p=0.038). c) The graphs indicate the total number IL-1 7A SFU per 106 
CD8+ T cells measured by ELispot compared to the number of IL-1 7 cells 
p er 106 CD8+ T cells as measured by JCS. p values were calculated using 
student 's two tailed unpaired t test, (*p =O. 03 7) and **p=O. 026). 
Note: In JCS, Unstimulated values were similar in all experiment time 
points and the background range was between 0. 00-0. 02%. 
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Fig 5.8: Comparative analysis of IL-17 A expression by lung KdGag197-
205 specific CD8+ T cells at acute, effector memory and following 
influenza-HIV challenge 
BALB!c (H-2d Background) mzce (n =5-10) were prime-boost immunized 
with FPV-HIVIVV-HIV (control vaccine) or FPV-HIV IL-13Ra2/ VV-HIV 
IL-13Ra2 (IL-13 inhibitor vaccine). At 3 days, 14 days, 8 weeks and 
influenza-HIV challenge, lung samples from each group were pooled, 
harvested and 4 x 106 cells were stimulated for 16-20 hrs with KGag197-205 
peptide and IL-1 7 A expression by CD8+ T cells was measured by 
intracellular cytokine staining. a) The FACS plots indicate pooled animals 
from each group. In all F ACS plots, the upper right quadrant (R3) indicates 
RI + R2 and the numbers indicate IL-1 7 A producing CD8+ T cells as a 
percentage (top) and also the gated number of events (bottom within 
brackets). b) The graph represents the percentage of CD8+ T cells 
expresszng IL-1 7 A where the unstimulated background value was 
subtracted. c) The graphs indicate the total number IL-1 7 A SFU per 106 
CD8+ T cells measured by EL/spot. Compared to the number of IL-1 7 cells 
per 106 CD8+ T cells as measured by JCS. Data are representative of two 
independent experiments 
Note: In JCS, Unstimulated values were similar in all experiment time 
points and the background range was between 0. 00-0. 02%. 
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5.5 Discussion 
Current data obtained from IL-17 A ELispot and ICS clearly indicated that there was a 
greater IL-17 A expression by KdGag197-205 specific CD8+ T cells following IL-13 
inhibitor vaccine at effector, memory, and following influenza-HIV challenge compared 
to the control vaccine and unimmunized controls. However, in IL-13 KO mice, where 
elevated IL-17 A expression was observed ( chapter 3), much lower IL-17 A expression 
was detected following IL-13 inhibitor vaccine in BALB/c mice. This can most likely 
be due to the transient inhibition of IL-13 by this vaccine. In summary, current results 
clearly indicate that IL-17 A expression is significantly modulated by the presence or 
absence of IL-13 in the cell milieu during vaccination. 
Following the novel IL-13 inhibitor vaccine, IL-17 A levels were highest at effector 
stage and following influenza-HIV challenge in both spleen and lung. This suggested 
that IL-17 A expression is mainly regulated at the peak of CD8+ T cell activity. 
Similarly, influenza-HIV challenge data obtained from IL-13 KO mice and IL-13 
inhibitor vaccine have shown enhanced protective immunity (Ranasinghe et al. 
submitted June 2012). Very similar to IL-13-/- mice, these mice showed lower weight 
loss compared to the mice that received FPV -HIV NV-HIV ( control vaccine). Similarly, 
IL-17 has shown to play role in vaccine mediated immunity against bacterial infections 
such as Helicobacter, Bordetella pertussis and Pseudomonas aerogenosa, where its 
induction by CD4+ T cells correlated with rapid bacterial clearance [32, 42, 193]. Recent 
studies have shown that vaccination against Mycobacterium tuberculosis followed by 
tuberculosis infection generated IL-23 induced IL- I 7 production by CD4 + T cells in the 
lung and induced long lasting memory immunity [21, 3 9]. Indeed, inclusion of IL-17 as 
a co-adjuvant in recombinant vaccine against Eimeria acervulina has shown to induce 
protection against the parasite [ 194]. In the context of viral infections, vaccination 
against rotavirus generated elevated IL-17 and IFN-y expression thereby reducing fecal 
shedding [37, 38]. Interestingly, other studies using IL-17-/- and STAT3coR_;_ mice 
have described that these IL-17 A secreting cells were not critical for viral clearance but 
instead regulated anti-viral immunity through additional mechanism such as neutrophil 
recruitment [195]. Wang et al. have shown that IL-17-/- mice infected with H5Nl 
influenza exhibited increased weight loss, reduced survival rate high lung pathology 
[196]. Also, the IL-17 A expression by the CD8+ T cells in the lung were associated with 
protective immunity against influenza virus via the recruitment of neutrophils [19]. The 
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above observations together with our findings clearly indicate that IL-1 7 A expression 
can be considered as a marker of protective immunity. 
As IL-13 is also involved in the regulation of high avidity CTLs, current data indicate 
that IL-1 7 A may also play an important role in modulating the avidity of the CTLs and 
protective immunity. Rahaman et al. have shown that IL-13Ra2 could enhance IL-4 
mediated STAT3 signaling indirectly [152, 197]. Furthermore, when IL-13 was added 
at the time or polarization of CD4+Thl 7 cells, there was decrease in the STAT3 
phosphorylation [70]. Accordingly, studies have shown that STAT3 plays an important 
role in the differentiation of CD4+ T cells into Thl 7 cells [198]. This STAT3 mediated 
differentiation of Thl 7 cells occurs through induction of IL-23R and transcription factor 
ROR-yt [199]. Taken together these findings, we can postulate that IL-13 inhibitor 
vaccine may regulate IL-17 A expression by HIV-specific CD8+ T cells through the up-
regulation of a STAT3 mediated signaling pathway. 
In summary, current data clearly indicated that IL-13 inhibitor vaccine can induce 
enhanced IFN-y and IL-17 A expression by HIV-specific CD8+ T cells. Data again 
substantiate that IFN-y does not modulate IL-1 7 A expression in HIV -specific CD8+ T 
cells. The greatly elevated IL-17 A expression following influenza-B!V challenge 
suggests that the production of IL-17 A by antigen specific CD8+ T cells could be a 
hallmark of protective immunity. Since IL-13 inhibitor vaccine also induced high 
avidity CD8+ T cells, data suggest that IL-17 A most likely play a direct or indirect role 
in CD8+ T cell avidity, which is consistent with the findings in chapter 3. 
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CHAPTER 6: General Discussion 
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General Discussion 
Th 17 cells, unlike Th 1 and Th2 are a newly discovered subset of T cells, which 
specifically produce range of Thl 7 family cytokines IL-17A to F [14]. Still there 
is great debate about the exact role of these Th 17 cells and specifically how these 
cells are regulated under different infection conditions. Majority of the studies in 
infection models have mainly focused on the role of IL-17 A in CD4+ T cells. 
These studies have shown that IL-17 A plays an important role in protective 
immunity [21, 200, 201]. In the context of HIV /SIV infection, loss of IL-17 
production in the intestinal mucosae has been associated with SIV /HIV disease 
progression in macaques [202, 203]. In HIV prime-boost vaccine model, 
Ranasinghe et al. have shown that IL-4 and IL-13 play a direct role in modulating 
T cell avidity and protective immunity [165], (Ranasinghe et al Submitted). The 
current study has now shown that IL-4/IL-13 cytokines regulate the IL-1 7 A 
expression in HIV-specific CD8+ T cells both at the transcriptional and 
translational level and IL-17 A plays an important role in protective immunity. 
This indicates that IL-17 A also plays an indirect role in modulating CD8+ T cell 
avidity. 
Following FPV-HIVNV-HIV prime-boost immunization, IL-4 KO mice elicited 
the highest IL-17 A expression, which suggested that IL-4 played a more 
predominant role in down regulation of IL-17 A in HIV-specific CD8+ T cells 
compared to IL-13 KO mice (fig 6.1 ). In IL-4 KO mice higher levels of TGF-~, 
IL-6, ROR-yt were also detected suggesting that the IL-17 A transcription in HIV-
specific CD8+ T cells was mainly regulated in an IL-4 dependent manner. 
Interestingly, our findings are consistent with allergic asthma studies where IL-4 
was shown to be the potent inhibitor of IL-17 A expression (Th2 cytokines in 
particular IL-4 is known to play a pivotal role in allergic asthma and airway 
hyperresponsiveness) [ 69]. These studies revealed that the fine balance of IL-4 
and IL-17 A could determine the severity of asthma [73]. 
Unlike what was reported in CD4+ T cells [68, 204], current data indicated that IFN-y 
did not suppress the IL-17 A expression as majority of IL-17 A secreting CD8+ T cells 
were also positive for IFN-y in KO mice (Fig 6.1). This indicated that in a vaccine 
setting, IL-17 A together with IFN-y mediates efficient viral clearance in CD8+ T cells. 
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The mRNA studies further substantiated our findings where following peptide 
stimulation both T-bet (transcription factor for IFN-y) and IFN-y were highly up 
regulated in CD8+ T cells obtained from IL-4-/- mice. Although, studies have shown 
that ROR-yt was the master transcriptional factor in differentiating/maintaining IL-17 A 
expression, our data indicate that TGF-~ plays an important role in the IL-17 A 
induction in CD8+ T cells [172]. Furthermore, current data also showed that IL-23a was 
not involved in the regulation of IL-17 A expression in HIV-specific CD8+ T cells, 
unlike what has been reported with Thl 7 CD4+ T cells [205, 206]. 
Granzyme B is thought to regulate IL-17 A expression, as IL-17 A expressing CD8+ T 
cells have shown to be less cytotoxic [181]. Interestingly, in the current study, HIV-
specific CD8+ T cells obtained from IL-13 KO mice produced the highest granzyme B 
and showed reduced IL-17 A expression whilst the IL-4 KO mice showed the highest 
IL-17 A expression but lower granzyme B. These observations were consistent with 
previous findings in our laboratory where IL-13 KO mice were found to express 
elevated granzyme B by HIV-specific CD8+ T cells compared to the other KO groups 
tested (fig 6.1) (Ranasinghe 2007). The IL-13 KO mice showed enhanced granzyme B, 
moderate IL-17 A, and IFN-y expression by HIV-specific CD8+ T cell. These results 
correlated well with our previous avidity studies, where FPV -HIV /VV -HIV vaccination 
of IL-13 KO mice showed high avidity effector and memory HIV-specific CD8+ T cells 
with better protective immunity fallowing a surrogate HIV challenge compared to IL-4 
KO mice (Ranasinghe 2009, Ranasinghe Submitted). 
The new IL-13 inhibitor vaccine (FPV-HIV IL-13Ra2/VVHIV-IL-13Ra2), also induced 
higher IL-1 7 A expressions in CD8+ T cells compared to the control vaccine (FPV-
HIV /VV-HIV), and were found to be better protective following a mucosal challenge 
(Ranasinghe et al submitted). However, compared to IL-13 KO mice, the WT BALB/c 
mice that received the IL-13 inhibitor vaccine were less protective and showed lower 
numbers of IL-17 A expressing HIV-specific CD8+ T cells (Ranasinghe et al SlJbmitted). 
This is not entirely surprising as unlike IL-13 KO mice where a complete lack of IL-13 
was found in the cell milieu, the novel IL- l 3Ra2 vaccine only inhibited IL-13 activity 
in a transient manner at the vaccination site. The current observations clearly indicate 
that IL~ 13 acts upon IL-17 and these two cytokines plays an important role in 
modulating CD8+ T cell avidity and protective immunity in mice. Even though some, 
studies contradict our findings for example, during respiratory syncytial virus infection 
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Fig 6.1 Schematic diagram depicting IL-17 A mediated protective 
immunity 
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elevated IL-17 A expression was reported to inhibit CD8+ T cell effector function and 
increase viral proteins [207] , majority of the studies have shown that elevated IL-17 A 
correlated with protective immunity. For example, elevated IL-17 and IFN-y expression 
following rota virus vaccination was associated with reduced shedding of the virus [3 7, 
38]. Similarly, CD8+T cells producing IL-17A in the lung were involved in protective 
immunity during influenza infection (Hamada et al. , 2009). Therefore, our studies 
indicate that the activity of IL-17 A largely depends upon presence or absence of IL-
4/IL-13 in the cell milieu and this can have a major impact on CD8+ T cell cytotoxicity 
and protective immunity (Fig 6.2). 
Collectively, data in this thesis clearly demonstrate that i) both IL-4 and IL-13 modulate 
the expression of IL-17 A by HIV-specific CD8+ T cells, where IL-4 play a more 
predominant role in this modulation than IL-13 and ii) in HIV-specific CD8+ T cells, 
TGF-~, IL-6 and ROR-yt mainly regulate the IL-7A expression. As IL-4 and IL-13 
significantly modulate CD8+ CTL avidity, results also indicate that IL-17 A is also an 
indirect player in the regulation of CD8+ T cells avidity and protective immunity. These 
finding suggest that in a vaccine context, together with IFN-y and Granzyme B, IL-1 7 A 
also can be used as a marker of effective cell mediated protective immunity. 
Future directions 
• This study mainly focused on the IL-17 A expression 1n systemic 
compartment. However, IL-17 A has shown to play an important role in the 
gut mucosae [208-210]. Therefore, assessing the IL-17 A expression in 
mucosa} CDS+ T cells (specifically gut) following IL-13 inhibitor vaccination 
would provide valuable insights into how IL-17 A is regulated at the 
mucoase in the context of an HIV-1 vaccine. 
• 
• 
In this study IL-4 was the main inhibitor of IL-17 A expression. Therefore, 
creating an HIV-1 vaccine that could inhibit both IL-4 and IL-13 has great 
potential to induce enhanced IL-17 A and enhanced cytotoxicity, which may 
offer better protective immunity. 
Also previous studies in our laboratory have shown that route of vaccine 
delivery can modulate IL-4 and IL-13 expression. Specifically, mucosa} 
immunization induces low IL-4/IL-13 expression by HIV-specific CDS+ T 
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cells compared to systemic delivery. Therefore, following systemic and 
mucosa} vaccine delivery assessing the IL-17 expression will also provide 
useful information on the importance of designing mucosa} vaccines for 
HIV-1. 
• IL-25 or IL-17E unlike IL-17 A belongs to the newest member of IL-17 
family and mediates Th2 immune response by inhibiting Thl and Thl 7 
response [78-81, 211]. Studies have shown that neutralization of IL-2 5 in 
an asthma model lead to the down regulation of IL-13 expression and a 
reciprocal increase in IL-17 A correlating to protective immunity against 
airway hyper responsiveness [212]. Therefore, future studies evaluating the 
role of IL-25 and IL-17 A regulation in HIV-specific CDS+ T cells may provide 
valuable information on how T cell avidity is modulated in-vivo. 
• Studies designed to further understand the mechanisms by which IL-17 A 
induce better cell mediated protective immunity will aid in the 
constructions of more effective future vaccines not only against HIV-1 but 
also for other chronic diseases. 
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Fig 6.2 Schematic diagram summarizing the expression of IFN-y, IL-
17 A and granzyme-B and CD8+ T cell avidity following prime-boost 
immunization 
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